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ABSTRACT 
 
Traumatic brain injury (TBI) is a widespread problem in the United States affecting thousands of 
individuals annually.  Due to our lack of understanding of the mechanisms of TBI, medical 
management of the functional deficits in these patients is difficult.  In this study, injury induced 
deficits in striatal dopamine neurotransmission was studied using rats injured by controlled 
cortical impact.  We identified specific decrease in the levels of phosphorylated tyrosine 
hydroxylase (TH) measured by Western blots in the striatum and substantia nigra at 1 week 
following TBI, suggesting a decrease in TH activity.  A direct measurement of TH activity by an 
in-vivo TH activity assay showed a correlating deficit in the injured animals.  Striatal dopamine 
release evoked by potassium stimulus using microdialysis probes was decreased in injured 
animals compared to shams at 1 week.  These results suggest deficits in presynaptic dopamine 
synthesis and release.  To reverse these deficits, nicotine which was previously demonstrated to 
enhance striatal dopamine signaling, was administered for 1 week following injury.  Rats that 
were treated with nicotine showed recovery of dopamine release and TH activity deficits.   
 
We have previously identified that TBI induces deficits in phosphorylation of striatal posynaptic 
protein: dopamine and cAMP regulated phosphoprotein 32 (DARPP-32), an important regulator 
of striatal dopamine signaling.  To assess if nicotine treatment can also reverse this deficit in 
DARPP-32 phosphorylation at threonine 34 (pDARPP-32-T34), Western blot was used.  There 
was no enhancement of pDARPP-32-T34 levels by nicotine treatment compared to saline 
controls.  Also, phosphorylation levels of molecules downstream of pDARPP-32-T34: 
extracellular signal-regulated kinase (ERK) and cAMP response element-binding protein 
(CREB) were not affected by nicotine treatment.  Behavioral experiments testing motor function 
by Beam Balance Test and Beam Walking Test and cognitive function by Morris Water Maze 
test showed no benefits of nicotine treatment.  The molecular results in this study suggest that 
nicotine may lead to activativation of multiple receptor signaling pathways that have opposite 
modulation of pDARPP-32-T34.  This study gives us a better understanding of the complex 
signaling pathways of striatal dopamine neurotransmission in the setting of TBI. 
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PREFACE 
 
My work with Dr. Dixon began in the summer of 2006 when I arrived in Pittsburgh.  At the time 
I had just attained my undergraduate degree in Bioengineering with 2 years of part time research 
in immunology, and neuroscience was a novel subject for me.  Although I’ve invested much time 
in learning bioengineering and immunology, the curiosity of neuroscience was what drove me to 
switch fields.  I was a bit apprehensive to make the switch, but deep inside my mind I felt that 
understanding the mechanism of consciousness was my greatest desire that I’ve had for years.   
 
Five years have quickly passed since then, and I truly feel that the decision was correct.  Over the 
years Dr. Dixon has guided me and transformed me in various ways.  Grantsmanship, oral 
presentation skills, and scientific writing skills are key skills I have gained under Dr. Dixon’s 
guidance.  Also, with the help of the thesis committee, I have grown to think as a scientist.  
Scientific facts are something one can gain from reading a book, but the skills to critically 
analyze data and communicate thoughts to others are not something attainable without 
mentorship. 
 
Other members of my lab James Bales, Youming Li, Michelle Ma, Hong Yan, Sherman Culver, 
and Kristin McFarlane have taught me various techniques over the years.  I appreciate their 
dedication as well as their patience to tolerate my somewhat obsessive personality.  In particular, 
I will miss the presence of Dr. James William Bales, who introduced an ounce of sanity in my 
research endeavors during the last three years. 
 xii 
 
Lastly, I’d like to close this preface with words of wisdom I will borrow from my father and Zhu 
Chi, a great Chinese philosopher.  My father had quoted this philosopher in his final lecture as a 
retiring professor of Seoul National University, Korea.  The few memorable lines were: 
 
 “Do not say you will learn tomorrow what you must learn today.   
Do not say you will learn next year what you must learn this year. 
It is easy for a young boy to gain age, but it is difficult for him to gain knowledge.   
Therefore, do not take even one second lightly.” 
 
As time passes by and I gain more knowledge, I realize that it is inevitable that I gain age, but 
impossible to learn to the degree I desire.  Yet, I will pursue learning until the last day of my life.  
This is the scholarly spirit that my father has passed on to me and the ideals that I will live by. 
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1.   Introduction and Background 
 
1.1   Traumatic Brain Injury in the United States 
 
Traumatic brain injury (TBI) is a widespread problem in the United States, causing 1.5 
million cases of death or emergency care annually (Nolan S, 2005).  Approximately 5.3 million 
individuals live with varying degrees of disability resulting from TBI in the U.S., and 70,000 to 
90,000 (Consensus Conference, 1999) have substantial loss of functioning as a long term 
outcome.  TBI occurs at an incidence of 200 per 100,000 people per year, most commonly by 
motor vehicle accidents, falls, and violence (Shames J et al., 2007).  The majority of patients 
may recover rapidly, but a large proportion of moderate to severely injured patients sustain 
permanent cognitive, emotional, and physical deficits.  In addition, TBI can result in various 
devastating complications such as seizures, hydrocephalus, infections, and behavioral and 
functional deficits.  As a result, there is a tremendous cost of medical care for these individuals 
not only for the immediate management but also for the long term rehabilitation.  Moreover, the 
loss of potential human resources among these individuals is incalculable. 
 
Because the causes of TBI are varied, such as motor vehicle accident, falls, violence, and 
sports related injury, the mechanisms of injury are also diverse.  The current primary 
classification system for TBI is the Glasgow Coma Scale (GCS), which categorizes cases into 
mild, moderate, and severe injury.  However, these categories do not explain the mechanism of 
injury, and patients with the same GCS score may have very different pathophysiology ranging 
from epidural hematoma, subdural hematoma, subarachnoid hemorrhage, and diffuse axonal 
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injury (Saatman et al., 2008).  The heterogeneity of injury and difficulty of categorization and 
management is thus a major issue for researchers and clinicians who specialize in TBI. 
 
Although TBI is a heterogeneous disease of various pathophysiological mechanisms, 
almost all cases of TBI cause deficits in cognitive function.  The long lasting consequences of 
cognitive impairment are often underreported and the mechanisms are often unclear.  
Neuropsychological tests looking at various aspects of behavior such as social function, 
cognitive abilities, and psychiatric symptoms at 10-20 years after TBI show significant 
behavioral impairment at such chronic time points (Hoofien D et al., 2001).  Individuals who 
have suffered TBI in the past have high incidence of personality changes and psychiatric issues 
such as depression, hostility, anxiety disorders, and post traumatic stress disorder.  These 
individuals also have decreased information processing speed and lower intellectual functioning 
amounting to difficulty in learning and social interaction.  
 
The economic burden resulting from TBI is estimated to be around $10 billion 
(Consensus Conference, 1999) annually for emergent care and rehabilitation.  On average, the 
cost for medical management of a person with severe TBI is estimated to range from $600,000 to 
$1,875,000.  This figure is likely an underestimate not including calculated lost earnings or cost 
to social service systems.  Moreover, there is an even larger loss in the economic value of human 
potential from the decreased contribution of these individuals to society due to the impairments 
in intellectual and social functioning capacity—a point that is often overlooked. 
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1.2 Current treatments for TBI 
 
Current treatment strategies for severe TBI focus on the control of cerebral edema and 
raised intracranial pressure, performed by administration of osmotic agents such as mannitol or 
hypertonic saline and decompressive craniectomy (Meyer et al., 2010).  The principle strategy 
behind using osmotic agents is to withdraw water from cerebral tissue, thereby reducing brain 
volume and pressure.  Surgical interventions allow decompression, which provides room for the 
swollen injured brain to reduce intracranial pressure when medical management fails.  Also, 
surgical interventions are useful for evacation of intracranial mass lesions such as hematomas.  
Hyperventilation was commonly used in the past in order to rapidly reduce intracranial pressure.  
However, aggressive or prolonged hyperventilation may in fact worsen outcomes because it 
reduces vascular perfusion and depletes bicarbonate levels.  Thus, only moderate 
hyperventilation is currently used in the clinical setting while cerebral oxygenation is being 
closely monitored (Muizelaar et al., 1991; Ralph and Lowes, 2009).   
 
Pharmacological treatments are also used in various settings of TBI.  Sedatives and 
antiepileptic drugs such as phenytoin and benzodiazepenes are used to prevent post traumatic 
seizures (Losiniecki and Shutter, 2010).  Barbiturates also prevent seizures and are used for 
management of uncontrollable intracranial pressures by reducing cerebral metabolism and 
cerebral blood volume.  However, adverse effects such as hypotension, adrenal insufficiency, 
and bone marrow suppression have been reported, and there is conflicting evidence as to whether 
the above treatments are more effective than conventional strategies of reducing intracranial 
pressure such as the use of mannitol (Meyer et al., 2010) 
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Corticosteroids were commonly used during the last decade in order to reduce post-
traumatic inflammation, which was believed to be one of the major mechanisms of secondary 
injury in TBI.  Although spinal cord injury studies have reported positive outcomes in motor and 
sensory function after corticosteroid treatment (Bracken et al., 1990, 1997), a large randomized 
trial of corticosteroids showed no beneficial effect and even increased the risk of death during  
the  2 weeks following TBI (Roberts et al., 2004). 
 
The use of hypothermia for therapeutic purposes in traumatic brain injury has gained 
much attention in the last decade.  It is believed to reduce inflammation and metabolic 
consumptions after injury.  In addition, it can attenuate excitoxic effects by attenuating glutamate 
release (Mueller-Burke et al., 2007) and alter the activity of matrix metalloproteinases thereby 
reducing blood-brain barrier permeability (Nagel et al., 2007).  A meta-analysis of eight studies 
(Peterson et al., 2008), however, showed no statistically significant effect on mortality or 
neurological outcome.  Prolonged hypothermia also has been associated with adverse effects 
such as sepsis, coagulopathy, and pneumonia.  Much research on hypothermia is now focused on 
the details of the protocol, as optimizing the duration and rate of cooling may result in positive 
outcome of the patients (De Deyne, 2010). 
  
In addition to these therapies, various pharmacological agents for TBI management have 
been attempted previously, ranging from cannabinoids, antioxidants, N-Methyl-D-aspartic acid 
(NMDA) receptor antagonists, and calcium channel blockers (Jain, 2008).  These agents were 
shown to be beneficial in animal models, but most clinical trials in humans found no efficacy.  In 
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a recent study comparing eleven pharmacological agents, only amantadine (a dopamine agonist 
and NMDA receptor antagonist) and CP-0127 (a bradykinin receptor antagonist) markedly 
improved behavioral and cognitive outcomes after TBI (Wheaton et al., 2009).  Pharmacological 
management of patients suffering from TBI is challenging due to the complexity of the 
mechanism of injury and heterogeneity of patients.  More research targeting specific mechanisms 
of injury or post injury deficits are needed for future development of pharmacological agents to 
treat TBI. 
 
 
1.3   Dopamine Deficits after TBI 
 
Changes in the dopamine system after TBI have been demonstrated in various studies in 
the past (Bales et al., 2009).  The pharmacological agents targeting the dopamine system can 
improve cognitive function in animals and humans after TBI.  Catecholamine agonist therapy has 
shown motor and cognitive improvement in both humans and animals (Phillips et al., 2003).  
Also, L-DOPA treatment which increases dopamine synthesis, enhances cognitive and motor 
function following TBI (Kraus and Maki, 1997; Koeda and Takeshita, 1998; .   
 
Methylphenidate (Kline et al., 1994, 2000) and D-amphetamine (Feeney et al., 1981; 
Sutton et al., 1989; Hovda et al., 1989; Hornstein et al., 1996), which increase synaptic dopamine 
levels by inhibiting dopamine transporter (DAT) function, enhance functional outcomes after 
experimental TBI.  Benefits in memory and attention (Evans et al., 1987), as well as increased 
information processing speeds were also previously reported (Willmott and Ponsford, 2009).  
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Moreover, amphetamine can facilitate neuronal plasticity and regeneration (Ramic et al., 2006).  
Outside the striatum, these agents not only inhibit the function of DAT, but also norephinephrine 
transporters.  This leads to an increase in synaptic norepinephrine levels in the neocortex 
receiving input from the neurons in the locus ceruleus and reportedly contributing to cognitive 
benefit. 
 
Amantadine is an agent that was originally used as an antiviral agent for Influenza A.  Its 
function as a psychostimulant gained wide interest in its use in neuropsychiatric diseases over 
time.  In the central nervous system, amantadine primarily functions as a noncompetitive 
antagonist of the NMDA receptor and is believed to increase extracellular dopamine 
concentrations by inhibiting  reuptake and facilitating dopamine synthesis (Von Voightlander 
and Moore, 1971; Bak et al., 1972).  It also induces postsynaptic effects, possibly by increasing 
postsynaptic dopamine receptor activation or by altering their conformation (Gianutsos et al., 
1985; Beers et al., 2005).  Amantadine administration following TBI has been shown to induce 
dopamine release when infused into the striatum by microdialysis (Takahashi et al., 1996).  In 
both clinical data (Sawyer et al., 2008) and animal models of TBI (Dixon et al., 1999), 
amantadine was demonstrated to facilitate neurorecovery.  As mentioned previously in Section 
1.2, meta-analysis of recent clinical trials showed marked cognitive benefit for using amantadine 
in TBI. 
 
In addition, alterations in the levels of striatal dopamine and proteins that synthesize and 
transport dopamine after injury have been reported in neurochemical studies. Dopamine levels 
increase at acute time points in several regions such as the striatum, hypothalamus, and frontal 
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cortex (Massucci et al., 2004; McIntosh et al., 1994).  The metabolism of dopamine, measured 
by the ratio of the dopamine metabolite dihydroxyphenylacetic acid (DOPAC) to dopamine, was 
increased at 1 hour after injury in the striatum (Massucci et al., 2004).   
 
There have been only a few reports on the levels of striatal dopamine receptors after TBI.  
One study demonstrated no changes in D2 receptors, but decreased numbers of D1 receptors 
immediately after TBI followed by an increase at 24 hours (Henry et al., 1997).  However, at 14 
days following TBI, no changes in D2 receptors were reported (Wagner et al., 2005, 2009).  
These studies also showed that the levels of striatal DAT is decreased at 14 days after TBI and 
that electrically evoked dopamine release, asmeasured by fast scanning cyclic voltammetry, is 
also decreased at that time. 
 
 
1.4 Dopamine Signaling in the Striatum 
 
The major dopamine projections in the CNS arise from the midbrain regions of the 
ventral tegmental area and substantia nigra pars compacta.  The dopaminergic axons arising  
from the ventral tegmental area project to nucleus accumbens and form mesolimbic pathway, 
whereas the dopaminergic axons arising  from substantia nigra project to the dorsolateral 
striatum to form the nigrostriatal pathway.  Midbrain dopamine projections from ventral 
tegmental area also reach into cortical regions such as the prefrontal cortex. 
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The striatum functions as the major input structure of the basal ganglia, a subcortical 
structure that has an important role in cognitive, emotional, and movement control (Hauber, 
2010).  In the striatum, nigrostriatal axons synapse onto medium spiny neurons that synthesize γ-
Aminobutyric acid (GABA).  Because medium spiny neurons represent 95% of neurons in the 
striatum, striatal dopamine signaling is regulated mostly by activation of these GABA-ergic 
postsynaptic neurons.  Once medium spiny neurons receive inputs, two output pathways can be 
activated: 1. Direct pathway projecting to substantia nigra and globus pallidus pars interna, and 
2. Indirect pathway projecting to subthalamic nucleus and globus pallidus pars externa (Hauber, 
1998).  Activation of the direct pathway (also known as striatonigral pathway) facilitates 
movement, whereas activation of the indirect pathway (also known as striatopallidal pathway) 
inhibits movement.  The activation of direct and indirect pathways occurs by dopamine release 
from striatal dopamine terminals activating different subtypes of dopamine receptors: D1 and D2 
receptors, respectively. 
 
Dopamine receptors belong to the G protein-coupled receptor superfamily, and these 
receptors are located on dendrites and cell bodies of neurons as well as axons and nerve 
terminals.  Dopamine receptors are categorized into either D1-like or D2-like receptors, with D1-
like receptors consisting of D1 and D5 receptors and D2-like receptors consisting of D2, D3, and 
D4 receptors.   In the striatum, D1 and D2 receptors were identified in the cell body and dendrites 
of medium spiny neurons (Levey et al., 1993).  Activation of D1-like receptors leads to activation 
of adenylate cyclase, which increases synthesis of 3’-5’-cyclic adenosine monophosphate 
(cAMP).  In turn, cAMP activates a second messenger important in activation various functions 
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of medium spiny neurons: protein kinase A (PKA).  However, D2-like receptors reduce adenylate 
cyclase activation by coupling to Gi/Go proteins (Vizi and Lajtha, 2008).   
 
Dopamine neurotransmission in the striatum has a significant role in brain function such 
as voluntary movement (Korchounov, 2008).  Dopamine receptors D1 and D2 influence long-
term potentiation and long-term depression, important mechanisms of synaptic plasticity in 
motor skill learning (Vizi and Lajtha, 2008).  Striatal dopaminergic signaling also plays a major 
role in spatial learning and memory (Mura A and Feldon J, 2003): rats that had bilateral lesions 
of nigrostrial dopaminergic system had profound deficits in acquisition task of Morris water 
maze.  These findings indicate the importance of the striatal dopamine system in both memory 
and motor function. 
 
 
1.5 Downstream signaling: DARPP-32, ERK, CREB 
 
When dopamine release activates receptors on medium spiny neurons, adenylate cyclase 
is activated and increase in PKA activity subsequently leads to phosphorylation of a 
phosphoprotein dopamine and cyclic adenosine 3’,5’-monophosphate-regulated phosphoprotein, 
32kDa (DARPP-32).  The protein DARPP-32 is present in 97% of medium spiny neurons 
(Matamales et al., 2009) and is involved in virtually all of dopamine mediated events ranging in 
biochemical, electrophysiological, and transcriptional events (Greengard et al., 1999; 
Svenningsson et al., 2004).  It has a central role in regulating neuronal excitability and induction 
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of long-term depression (LTD) and long-term potentiation (LTP), which form synaptic plasticity 
and serve as the basis of learning and memory (Calabresi et al., 2000). 
 
 
 
Figure 1.  Striatal dopamine signaling in medium spiny neurons.  Dopamine activation of 
D1 receptors activates PKA signaling pathway and activation of D2 receptors inhibits PKA 
signaling pathway.  Activation of PKA leads to phosphorylation of T34 site of DARPP-32, 
which then inhibits PP-1.  D1 and D2 receptors are depicted in the same neuron for conceptual 
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simplicity; most striatal medium spiny neurons express only D1-like receptors or D2-like 
receptors, and not both. 
 
DARPP-32 is present in both striatonigral neurons of the direct pathway activated by D1 
receptors and striatopallidal neurons of the indirect pathway activated by D2 receptors.  As 
previously mentioned, D1 receptor activation by dopamine is followed by an increase in activity 
of adenylate cyclase (Fig. 1).  This further leads to activation of PKA, which phosphorylates 
DARPP-32 in one of its two major phosphorylation sites: threonine-34 (T34).  This would in turn 
cause strong inhibition of protein phosphatase 1 (PP-1), which has numerous substrates, such as 
neurotransmitter receptors, ion channels, and other phosphatases.  Inhibition of PP-1 will activate 
transcription factors such as cAMP response element binding protein (CREB) via extracellular 
regulated kinase (ERK) pathway. This in turn would induce activation of genes important for 
synaptic plasticity.  
 
Activation of D2 receptor by dopamine will inhibit adenylate cyclase as well as cause 
phospholipase C and protein phosphatase 2B (PP-2B) activation (Nishi et al., 1997).  Since PP-
2B is a strong phosphatase that can dephosphorylate DARPP-32 phosphorylated at T34 
(pDARPP-32-T34), this will lift the inhibition on PP-1.  Thus, depending on the activation of D1 
or D2 receptors, there is a differential regulation in the activity of DARPP-32.  This is in 
agreement with previous electrophysiological and gene transcriptional data that demonstrate 
dopamine’s stimulatory effect via D1 receptors and inhibitory effect via D2 receptors (Gerfen et 
al., 1990; Robertson et al., 1990; West et al., 2002). 
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Figure 2. Western blot time course of striatal DARPP-32 (a) and pDARPP-32-T34 (b).  
From 6 hours to 4 weeks, there is no change in protein levels of DARPP-32 (a), but there is a 
decrease in p-DARPP-32-T34 (b) in the injured animals’ striata that are both ipsilateral and 
contralateral to the side of injury. (SC = sham contralateral, IC = injured contralateral, SI = sham 
ipsilateral, II = injured ipsilateral, *p≤0.05)  Figure from (Bales, 2010). 
 
Data previously generated by other members of the Dixon  laboratory have shown that 
TBI decreases the levels of pDARPP-32-T34 from 6 hours to 4 weeks after injury in rats (Fig. 
2).  Although phosphorylation of DARPP-32 is altered, there is no alteration in total DARPP-32 
protein levels.  Since pDARPP-32-T34 has an inhibitory effect on PP-1 activity, the decrease in 
pDARPP-32-T34 may cause an increase in PP-1 activity.  In accord with these data, the activity 
of striatal PP-1 increases at 1 day and 2 weeks post injury (Bales, 2010).  In addition, other 
previous data showed that intraperitoneal injection of PP-2B inhibitor FK506 after TBI can 
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reverse this deficit in pDARPP-32-T34 (Fig. 3).  Thus, there is a major role of PP-2B in reducing 
pDARPP-32-T34 following TBI. 
 
Another major regulation site for activity of DARPP-32 is threonine-75 (T75).  
Phosphorylation of T75 by cyclin dependent kinase 5 (cdk5) causes DARPP-32 to function as an 
inhibitor to PKA. This in turn will prevent T34 phosphorylation.  Thus, DARPP-32 acts either as 
an inhibitor of PKA or PP-1 depending on the phosphorylation of T34 or T75.  This differential 
function of DARPP-32 depending on the phosphorylation of two sites makes it a bifunctional 
signaling molecule. 
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Figure 3.   FK506 treatment following TBI.  Animals were injected with single dose of 
FK506 (2 mg/kg, suspended in 0.9% saline) 5 minutes after injury.  Western blots of pDARPP-
32-T34 demonstrated full reversal of TBI induced deficit with FK506 treatment. (*p≤0.05 
compared to sham ipsilateral vehicle).  Figure from (Bales, 2010). 
 
Downstream of DARPP-32 is the extracellular signal-regulated kinase (ERK), which has 
a major role in learning and memory.  ERK is activated by phosphorylation, leading to its 
subsequent phosphorylation of CREB.  Although ERK activation can occur downstream of 
DARPP-32, PKA can also directly activate ERK, as shown in (Fig. 1).  The importance of ERK 
in learning and memory is evidenced by its necessity in LTP induction and behavioral tests for 
learning and memory. 
 
The role of ERK in learning and memory was most extensively investigated in the 
hippocampus in the past.  In hippocampal slices, LTP-inducing high frequency stimulation 
activates ERK (English and Sweatt, 1996). Inhibition of the ERK cascade (English and Sweatt, 
1997; Impey et al, 1998) attenuates LTP formed by this high frequency stimulus.  Behaviorally, 
rats subjected to fear conditioning tasks, a form of associative learning, had increased levels of 
phosphorylated ERK (Atkins et al., 1998).  Pharmacological inhibition of MEK, the kinase 
upstream of ERK, also inhibited the ERK cascade and abolished fear conditioning.  This study 
also showed inhibition of LTP induction when MEK inhibitor was applied.  Rats subjected to 
spatial learning in Morris Water Maze also show increased phosphorylated ERK immediately 
after training (Blum et al., 1999).  Moreover, infusion of a MEK inhibitor decreased long term 
spatial learning in these animals, again verifying the importance of ERK in memory formation.  
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Similarly, treatment of mice with SL327, a MEK inhibitor inhibited cocaine induced locomotion 
(Valjent et al., 2005). 
 
The role of ERK in striatal learning has also been demonstrated in the past by 
electrophysiological and  behavioral studies.  The formation of LTP by in vivo electrical 
stimulus of cortico-striatal circuit (Carpier and Deniau, 1997) induces ERK activation (Sgambato 
et al., 1998) and immediate early genes such as c-fos, zif268, MAP Kinase phosphatase-1.  
Activation of ERK leads to activation of downstream transcription factors such as CREB and 
Elk-1, which induce immediate early gene transcription (Deng and Karin, 1994).  In rodent 
behavioral studies, molecular changes in the striatum followed several forms of learning such as 
associations between action and outcome and motor tasks.  Increases in phosphorylation of 
striatal ERK and c-fos occurred when mice were subject to motor skill learning using 
accelerating rotarod task (Bureau et al., 2010).  Injection of inhibitors of ERK signaling such as 
PD98059 or SCH237 inhibited motor skill learning, demonstrating the importance of ERK 
signaling in memory involving the striatum.  Similarly, ERK phosphorylation (Shiftlett et al., 
2008) as well as the activation of transcription factor CREB by phosphorylation (Shiftlett et al., 
2009) in the nucleus accumbens increases after training to produce associations between an 
auditory tone and food. 
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1.6 TBI and dysregulation of α-synuclein 
 
Alpha-synuclein (α-syn) is a soluble protein found in presynaptic terminals of various 
parts of the brain.  It is believed to play a particularly important role in synucleinopathies such as 
Parkinson’s Disease, dementia with Lewy bodies, and multiple system atrophy, though the exact 
mechanism has not been demonstrated thus far.  Past studies have shown that α-syn may inhibit 
activity of tyrosine hydroxylase (TH) (Perez et al., 2002) and aromatic amino acid decarboxylase 
(AADC) (Tehranian et al., 2006), enzymes responsible for dopamine synthesis, by direct 
physical interaction as demonstrated by immunoprecipitation.  Thus, disruptions in α-syn levels 
by its increased expression or aggregation can cause dysregulation of dopamine biosynthesis.  
Also, α-syn has been shown to inhibit DAT function by trafficking DAT away from plasma 
membrane into the cytoplasm (Wersinger et al., 2003, 2004).  Overall, pathologic processes that 
lead to loss of α-syn equilibrium then can lead to dysregulation of both biosynthesis and 
transport of dopamine.  Studies on α-syn knock out mice show nigrostriatal dopaminergic 
deficits in terms of its release, tissue content, and amphetamine- induced locomotion (Abeliovich 
et al., 2000), supporting the idea that α-syn is an important protein in the modulation of 
dopamine activity. 
 
In a previous study that I have performed, α-syn levels in the striatum of TBI rats were 
shown to be drastically elevated compared to the levels in sham rats at 1 week post injury (Fig. 
4).   By 4 weeks, the levels of α-syn in injured animals were reduced to levels comparable to 
those seen in sham animals.  Because α-syn can modulate the activity of dopamine regulating 
proteins, this temporary upregulation of α-syn protein may be related to dopamine dysregulation.  
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Increased levels of α-syn may inhibit the activity of TH and AADC, decreasing dopamine 
synthesis and possibly contributing to deficits in striatal dopamine neurotransmission previously 
explained in sections 1.4 and 1.5. 
 
   
 
Figure 4.  α-syn levels in striatum measured by Western blot.   There is a drastic 
upregulation of striatal α-syn levels at 1 week post TBI.  By 4 weeks, the increases are reversed. 
(* = p≤0.05) 
 
Although the level of α-syn is increased in the injured animals at 1 week, the tissue level 
of dopamine in injured animals at 1 week is not different from those of sham animals (Massucci 
et al., 2004).  However, α-syn increase may still inhibit dopamine synthesis, decreasing 
potassium stimulus evoked dopamine release which will be shown in Chapter 2.  In addition, the 
recovery of potassium stimulus evoked dopamine release in the injured striatum at 4 weeks will 
be shown, correlating with the return of α-syn to sham levels.  However, whether this α-syn 
increase occurs specifically in dopamine terminals or other regions of the striatum has not been 
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demonstrated.  This is a question left for future studies using immunohistochemistry 
experiments. 
 
 
1.7 The Effects of Nicotine and Nicotinic Agonists: Behavioral Aspect 
 
Nicotine is a major neurostimulant that enhances cognitive function in both humans and 
animal models (Poorthuis et al., 2009).  Activation of nicotinic acetylcholine receptors (nAChRs) 
affects cholinergic signaling and other neurotransmitter systems that interact with the cholinergic 
system such as dopamine, leading to improvements in learning, memory, and attention.  Acute 
injection of nicotine improved rats’ performance on 16-arm radial maze, a measure of working 
memory (Levin et al., 1997).  Similarly, synthetic nAChR agonists such as 
dimethylaminoethanol (Levin et al., 1995), AR-R17779 (Levin et al., 1999), ABT-418 (Decker 
et al., 1994), and TC-1734 (Gatto et al., 2004) were all shown to improve working memory.  
Even with chronic nicotine infusion, this benefit in memory function was not diminished, and the 
benefits persisted even up to 4 weeks after withdrawal (Levin et al., 1990, 1992).  As chronic 
treatment would be necessary in managing neurodegenerative diseases or acute brain injuries, 
this property was clinically valuable.    
 
Nicotine and nAChR agonists have been shown to improve not only working memory, 
but also attention in more recent studies.  These experiments tested the rats’ abilities to pay 
attention to visual signals then to make correct choices by pressing on the levers that correlated 
with the signals, and demonstrated a benefit of nicotine and nAChR agonist (Rezvani et al., 
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2002; Rezvani and Levin, 2003; McGaughy et al., 1999).  In a similar attention test known as the 
five-choice serial reaction time task, a nicotine agonist SIB-1553A improved performance of rats 
as well as monkeys (Terry et al., 2002). 
 
Nicotine treatment also improves symptoms in several human diseases characterized by 
cognitive deficits.  In Alzheimer’s Disease, nicotine skin patch or intravenous delivery improves 
memory function (Newhouse et al., 1999; Parks et al., 1996) and learning (Wilson et al., 1995).  
In addition, nicotine application by skin patch (White and Levin, 1999) or subcutaneous injection 
(Jones et al., 1992) improved attention in Alzheimer’s Disease patients.  Similarly, in patients 
with Schizophrenia, cigarette smoking was shown to improve auditory gating (Adler et al., 
1993).  Schizophrenia patients have decreased nAChR in the hippocampus (Freedman et al., 
1995) and self-medication is a prevalent among them.  These findings support the notion of 
cognitive benefit of nicotine administration for Schizophrenia. 
 
Application of nicotine or nAChR agonists in the setting of acute brain injury improves 
cognitive function.  In rats with cortical lesion induced by electrical current, nicotine injection 
either pre or post injury resulted in improvement of memory and cognitive function (Brown et 
al., 2000).  These rats had better performance in the Morris Water Maze than the vehicle treated 
group for both the acquisition (learning test) and probe (memory test) trials, demonstrating 
improvement in both learning and memory.  In the setting of TBI, dietary supplementation of 
choline, which specifically activates α7 nAChRs, improved Morris Water Maze performance, 
and increases the levels of α7 nAChRs and tissue survival (Guseva et al., 2008).  Similarly, 
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intermittent injection of nicotine treatment for 11 days after TBI also improved acquisition and 
retention of spatial memory (Verbois et al., 2003a). 
 
Post TBI injection of cytidine-5’-diphosphate-choline (CDP-choline), a compound 
closely related to choline, also result in improvement of Morris Water Maze performance (Dixon 
et al., 1997).  CDP-choline treatment has also been shown to improve outcomes following stroke 
in clinical trials (Clark, 2009) and reduce memory problems and cognitive dysfunction in elderly 
patients with Alzheimer’s Disease (Conant et al., 2004).  However, it is not clear if these 
beneficial effects of CDP-choline treatment were due to increased choline to activate nAChRs or 
increased acetylcholine to activate all acetylcholine receptors.  Treatments using other specific 
agonists for nAChRs also induce cognitive benefit.  An agonist for nAChRs, AR-R1779 
increases social recognition memory in rats (Van Kampen et al., 2004) and nAChR agonist GTS-
21 improves learning and memory in aged rats (Young et al., 2007).  Also AZD0328, a nAChR 
agonist, was shown to improve learning and attentional process in rats (Sydserff et al., 2009). 
 
 
1.8  The Effects of Nicotine and Nicotinic Agonists: Nicotinic Receptors 
 
Nicotinic acetylcholine receptors are ligand-gated ion channel receptors that increase 
cellular permeability to Na+ and Ca2+ when activated.  As pentameric structures, there are 5 types 
of α subunits and 3 types of β subunits that nAChRs can be composed of.  The majority of 
striatal nAChRs are α4 and β2 containing nAChRs (α4β2), and this subtype is also most 
commonly found in dopaminergic terminals (Wonnacott et al., 2000).  Depending on the 
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composition of these receptors, they can have different sensitivities to nicotine (Salminen et al., 
2007) and firing patterns (Meyer et al., 2008).  Another prevalent nAChR is the α7 receptor 
expressed at glutamateric terminals (Salminen et al., 2004; Grady et al., 1992).  Since medium 
spiny neurons receive their major inputs from both glutamate and dopamine terminals, nicotine 
activates striatal signaling by both glutamate and dopamine (Fig. 5).  
 
 
 
Figure 5.  Simplified diagram of nicotine’s effect on striatal neurotransmitter release.  
Nicotine in the striatum activates α7 receptors on glutamate terminals and α4β2 receptors on 
dopamine terminals.  Thus, both neurotransmitters are released to activate the medium spiny 
neurons when nicotine is administered. 
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One of the molecular findings after chronic nicotine or nicotinic agonist treatment is the 
upregulation of nAChR.  In vitro, chronic nicotine treatment of SH-SY5Y cells upregulates the 
expression of α7 and α3 nAChR (Peng et al., 1997).  This upregulation by nAChR can also occur 
in vivo in rats treated with nicotine for 7 days post TBI using osmotic minipumps (Verbois et al., 
2003b).  Moreover, the TBI induced deficits in nAChR expression are attenuated with choline 
treatment (Guseva et al., 2008).  Delivering nicotine by intraperitoneal injection also increased 
the number of nAChRs (Verbois et al., 2003a).  
 
 
1.9 The Effects of Nicotine and Nicotinic Agonists: Striatal Dopamine  
 
Nicotine treatment has been previously shown to induce upregulation of the levels of 
tyrosine hydroxylase (TH).  The contribution of intracellular Ca2+ in TH synthesis was shown by 
a study where blockade of L-type Ca2+ channel prevented c-fos and TH mRNA upregulation 
after nicotinic receptor activation (Craviso et al., 1995).  These studies demonstrated that 
nicotine increases intracellular Ca2+ and that TH gene expression was Ca2+ dependent.  Previous 
studies also show that dopamine release in the striatum can be enhanced by nicotine (Marshall 
DL et al., 1997; Rahman SJ et al., 2003) or nAChR agonist treatment (Sydserff et al., 2009). 
 
Activation of nAChRs by nicotine administration in striatal slices leads to either decrease 
or increase of pDARPP-32-T34 in a dose dependent manner (Hamada et al., 2004).  At a lower 
dose of nicotine (1μM) in mouse neostriatal slices, there was a decrease in pDARPP-32-T34, 
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which is blocked by pretreatment with D2 receptor antagonist raclopride.  However, at a higher 
dose of nicotine (100μM), there was an increase in pDARPP-32-T34, which is blocked by 
pretreatment with D1 receptor antagonist SCH23390.  Thus, this study supports the idea that low 
concentrations of nicotine induce D2 receptor dependent decreases in pDARPP-32-T34, and high 
concentration nicotine induces D1 receptor dependent increase in pDARPP-32-T34.  This dose 
dependence of nicotine is possible since α7 receptors and α4β2 receptors have different affinities 
for nicotine.  Since α4β2 receptors have much higher binding affinity (Ki = 0.6-10 nM) than α7 
receptors (Ki = 400-15,000 nM), low dose nicotine will activate mostly α4β2 receptors, and thus 
affect dopaminergic terminals.  This will stimulate low level dopamine release onto the medium 
spiny neurons and activate D2 receptors, which have a higher affinity for dopamine.  However, 
high dose nicotine will activate both α7 and α4β2 receptors.  The activation of α7 receptors may 
lead to release of glutamate from the glutamatergic terminals synapsing on to dopaminergic 
terminals, causing a more robust release of dopamine.  At higher levels of dopamine release, 
primarily D1 receptors are activated.  Thus, nicotine concentration will determine which of the 
dopamine receptors become activated and whether pDARPP-32-T34 levels increase or decrease. 
 
Aside from enhancing striatal dopamine signaling, nicotine has been demonstrated to 
have neuroprotective function in the setting of nigrostriatal injury and Parkinson’s disease.  
Epidemiological studies showed that nicotine administration has a protective effect in the 
dopaminergic system.  The incidence of Parkinson’s disease in cigarette smokers is 
approximately one-half of that of age-matched non smokers (Quik and Kulak, 2002).   In 
parkinsonian animals, nicotine is neuroprotective against degeneration of the nigrostriatal 
system, and in patients with Parkinson’s disease, nicotine attenuates dyskinesia (Quik M et al., 
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2009; Huang LZ et al., 2009, Parain K et al., 2003).  In animals treated with nicotine, 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced nigrostriatal dopaminergic neuronal loss 
was greatly reduced (Janson et al., 1988b, Maggio et al., 1998, Parain et al., 2003).  Nicotine 
administration also reduced the loss of striatal dopamine after hemitransection of nigrostriatal 
fibers (Janson et al., 1988a; Janson et al., 1991).  In a rat model of Parkinson’s disease by 
rotenone, nicotine attenuates motor deficits and dopamine neuronal cell loss in substantia nigra 
(Takeuchi et al., 2009).  Nicotine treatment also prevented striatal dopamine loss, increased 
dopamine turnover, and dopamine terminal loss induced by 6-hydroxydopamine (Costa et al., 
2001; Ryan et al., 2001).  Thus, the beneficial effect of nicotine in the setting of striatonigral 
injury has drawn much interest in its possible use as a therapy. 
 
 
1.10 Aims 
 
Various studies in the past using pharmacological agents that affect the dopamine system 
have been found  to hasten functional recovery following TBI in both humans and animals.  
Moreover, proteins that regulate dopamine synthesis, release, and transport are altered following 
TBI at different time points.  Because dopamine signaling has a major role in both motor and 
cognitive function, this study investigated the specific mechanisms of striatal dopamine deficit 
and the possibility of reversing this deficit by a pharmacological agent, nicotine.  This study was 
conducted in four phases to answer the major hypothesis:  TBI induces deficits in striatal 
dopamine synthesis and release, which impairs postsynaptic signaling, factors that can be 
reversed by treatment with nicotine. 
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To answer the major hypothesis, 4 specific aims were followed throughout this study: 
• Aim 1 (Chapter 2): Determine if there are deficits in striatal TH activity and dopamine 
release after TBI. 
• Aim 2 (Chapter 3): Determine if TH activity and dopamine release deficits after TBI are 
restored by nicotine treatment. 
• Aim 3 (Chapter 4): Determine if enhancing TH activity and dopamine release can reverse 
the deficits in DARPP-32 activation and its downstream molecules.  
• Aim 4 (Chapter 4): Determine if enhancing striatal dopamine signaling by nicotine 
treatment results in cognitive and motor improvement in rats.  
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2. Alterations in Tyrosine Hydroxylase and Dopamine Release After TBI 
 
2.1 Introduction 
 
Tyrosine hydroxylase is a rate-limiting synthesis enzyme for the catecholamines such as 
dopamine and norepinephrine.  Though TH is responsible for synthesis of both catecholamines, 
striatal tissue contains very small levels of norepinephrine.  Thus, striatal TH represents the 
presence of dopaminergic fibers (Hokfelt et al., 1977; Anden et al., 1964).  Tyrosine hydroxylase 
is responsible for the conversion of amino acid tyrosine, which is transported across the blood-
brain barrier, into L-DOPA inside catecholaminergic neurons.  Subsequently, L-DOPA is 
converted into dopamine by the enzyme AADC.  Since the activity level of AADC is much 
greater than that of TH, L-DOPA is instantaneously converted into dopamine upon synthesis by 
TH (Vizi and Lajtha, 2008).  Due to its rate-limiting activity in dopamine synthesis, TH is one of 
the most commonly monitored enzymes for studying dopaminergic neuron’s function. 
 
Tyrosine hydroxylase regulates catecholamine biosynthesis either by phosphorylation or 
transcription.  Phosphorylation changes the activity levels of TH immediately, but transcriptional 
regulation to change the protein levels of TH increases the capacity for catecholamine synthesis 
in the long term.  There are four commonly reported sites of phosphorylation in TH:  serine 
residues 8, 19, 31, and 40.  Each site has a specific major kinase that regulates its 
phosphorylation: serine 19 is regulated by Ca2+/calmodulin-dependent protein kinase II 
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(Campbell et al., 1986), serine 31 is regulated by ERK1/2 (Haycock et al., 1992), and serine 40 is 
regulated by protein kinase A (PKA) (Haycock and Haycock, 1991).   
 
Increased activity of TH has previously been associated with phosphorylation of TH at 
the serine 40 (pser40TH), and direct activation does not occur by phosphorylation of  serine 19 
(pser19TH) (Lindgren et al., 2000), (Harada et al., 1996), although the binding of 14-3-3 proteins 
to pser19TH enhances pser40TH phosphorylation and TH activity (Kleppe et al, 2001; 
Bobrovskaya et al. 2004).  Phosphorylation of serine 40 leads to an increase in TH affinity to 
tetrahydrobiopterin, a cofactor required for L-DOPA synthesis, causing increased TH activity 
(Dunkley et al., 2004).  Also, phosphorylation of TH leads to changes in its interaction with 
dopamine: dopamine binds to unphosphorylated TH and inhibits its activity (Daubner et al., 
1992), (Gordon et al., 2008).  However, when phosphorylation at serine 40 occurs, 
catecholamine is released  from TH.  This relieves dopamine’s inhibitory feedback on TH, 
increasing the activity of TH.  The activity of TH is also complicated by the possible interactions 
between phosphorylation sites: serine 19 phosphorylation may alter the conformation of TH such 
that serine 40 phosphorylation occurs at an increased rate (Dunkley et al., 2004).  Thus, a better 
understanding of TH activity can be gained by investigation of both pser19TH and pser40TH.   
 
The experiments in this chapter focused on Aim 1: Determine if there are deficits in 
striatal TH activity and dopamine release after TBI.  The alteration in dopamine synthesis was 
first studied by assessing TH levels and TH activity.  To investigate both short term and long 
term changes in dopamine synthesis, total TH levels and phosphorylated TH levels were studied.  
Striatal TH, pser40TH, and pser19TH levels were monitored by Western blot at 1 day, 1 week, 
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and 4 weeks after injury.  Then, it was followed up using an in-vivo TH activity.  A PKA activity 
assay was also used to associate its role in modulating pser40TH levels.  In addition, potassium 
stimulus-evoked dopamine release was assessed using a combination of microdialysis and high 
performance liquid chromatography (HPLC). 
 
 
2.2 Materials and Methods 
 
2.2.1   Animals 
 
One hundred and three male Sprague-Dawley rats (Harlan Laboratories) weighing 280-
350 grams were used for this study.  All experiments were performed according to the guidelines 
for Care and Use of Laboratory Animals set by the University of Pittsburgh.  The Institutional 
Animal Care and Use Committee approved all the experiments in this study.  Animals were 
housed in 12 h light/dark cycle with food and water given ad libitum. 
   
2.2.2   Surgery 
 
Animals were injured by the controlled cortical impact (CCI) device as previously 
described (Dixon et al., 1991).  The rats were first anesthetized using 5% isoflurane in 2:1 ratio 
of nitrous oxide: oxygen and endotracheally intubated.  After intubation, animals were mounted 
on a stereotaxic frame and secured by incisor bar and ear bars.  Mechanical ventilation 
maintained anesthesia with 2% isoflurane in 2:1 N2O/O2  while the animals were prepared for 
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surgical exposure of the skull.  The head was shaved then cleaned using povidone-iodine.  After 
a midline incision exposed the skull from bregma to lambda, a retractor was placed to expose the 
skull.  Then, parasagittal craniectomy was made with the center of craniectomy at (AP: +4.0 mm, 
L: +2.8 mm), making a window large enough for 6mm tip of the CCI device.  For injured 
groups, 2.6-3.2 mm deformation depth (severe injury) at 4 m/s was given while sham groups 
received only craniectomy.  After the impact, the incision site was closed with silk sutures and 
animals were taken off the anesthesia.  Animal recovery was monitored until tail pinch and 
righting reflex returned.  After recovery, the animals were returned to the home cages in the 
animal facility. 
 
2.2.3   Western blot 
 
Rats were anesthetized using sodium pentobarbital (100 mg/kg) and sacrificed by 
decapitation at 1 day, 1 week, or 4 weeks after surgery (n=6 for each group).  Brains were 
dissected on a chilled ice plate and striata and substantia nigra ipsilateral and contralateral to the 
injury were frozen in liquid nitrogen and stored at -70˚C until preparation.  Tissues were 
prepared by sonicating in a lysis buffer (0.1 M NaCl, 0.01 M Tris-HCl (pH 7.6), 0.001 M EDTA 
(pH 8.0), 1 μg/ml phenylmethylsulfonyl fluoride, Phosphatase Inhibitor Cocktails 1 and 2 (1:100, 
Sigma, St. Louis, MO), Protease Inhibitor Cocktail (Complete Mini, Roche Applied Science, 
Mannheim, Germany)).  The sonicated tissues were centrifuged at 13,000 х g for 30 min and 
supernatants were used for Western blot.  Using a BCA protein assay kit (Pierce, Rockford, IL), 
samples containing 40 μg of protein were electrophoresed on 10% SDS-polyacrylamide gels, 
transferred to polyvinylidene fluoride membranes, and blocked by 5% bovine serum albumin 
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(BSA) (Sigma, St. Louis, MO) in 0.05 M TBS with 0.05% Tween-20 (TBST) for 1 h.   The 
membranes were incubated with anti-TH (1:10,000, Millipore) anti-pser19TH (1:1,000, 
Millipore), or anti-pser40TH (1:1,000, Millipore) overnight, then washed with TBST and 
incubated for 1 hour at room temperature with anti-mouse or anti-rabbit immunoglobulin G 
conjugated to peroxidase (1:20,000, Pierce).  Membranes were treated for chemiluminescence 
(Western Lighting, Perkins Elmer, Boston, MA) and TH, pser19TH, and pser40TH signals were 
visualized by exposing the membranes to autoradiographic X-ray film from 10s to 1 min.  
Afterwards, membranes were stripped using 100 mM glycine pH 2.3 at 55˚C for 1 hour, 
incubated with anti-β-actin monoclonal antibody (1:10,000, Sigma-Aldrich) for 1 hour, then 
incubated with anti-mouse immunoglobulin G conjugated to peroxidase.  The same steps were 
taken as described above to visualize β-actin.  To measure the optical density of Western blots, 
Scion Image PC software (Frederick, MD) was used.  Optical densities of TH, pser19TH, and 
pser40TH were normalized by β-actin of each blot, and the values displayed are given as a 
percentage compared to sham tissue levels for each respective side.   
 
2.2.4   PKA Activity Assay 
 
The activity level of PKA was measured using a commercially available kit (Promega, 
Madison, WI).  Briefly, the ipsilateral tissue homogenates used for Western blots were 
suspended in PepTag PKA 5x reaction buffer, Peptag A1 peptide, and PKA activator 5x 
solutions.  These mixtures were incubated at room temperature for 30 minutes.  The reaction was 
stopped by placing the mixture in boiling water for 10 minutes.  Glycerol (30%, 1 μL) was added 
to the mixture, and samples were loaded onto 0.8% agarose/Tris-HCl gel.  The gels were run at 
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100 V until separation of phosphorylated and unphosphorylated samples became apparent.  The 
gels were then scanned using Kodak Image Station 440CF.  The optical densities of the 
phosphorylated product from the PKA reaction were then normalized to total protein level in 
each sample using NIH Image J software.  PKA activity levels were reported with respect to 
sham striatal PKA activity levels. 
 
2.2.5   In-vivo TH Activity Assay 
 
As described in (Urbanavicius et al., 2007), in vivo TH activity was assessed by 
quantifying L-DOPA accumulation in striatal tissue after inhibiting AADC with 3-
hydroxybenzylhydrazine (NSD-1015) (Sigma, St. Louis, MO).  Thirty minutes before sacrifice, 
rats were intraperitoneally injected with NSD-1015 (100 mg/kg, suspended in 0.9% saline).  
Ipsilateral striata were dissected out, immediately frozen in liquid nitrogen, and stored at -70˚C 
until neurochemical analysis.  On the day of analysis, the tissues were weighed and sonicated in 
0.2 M HClO2 at 0.2 mg/μL concentration.  The samples were then centrifuged at 13,000 х g for 
30 min and supernatants were used to quantify L-DOPA levels by HPLC. 
 
2.2.6   Microdialysis 
 
Artificial cerebrospinal fluid (ACSF) containing 126.5 mM NaCl, 2.4 mM KCl, 1.1 mM 
CaCl2, 0.83 mM MgCl2, 27.5 mM NaHCO3, and 0.5 mM KH2PO4 was used for this experiment.  
The microdialysis probe (SciPro, Sanborn, NY) with the following specification (membrane 
length: 3mm, diameter: 0.6mm, permeability cut-off: 35kDA) was implanted 1 hour before the 
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experiment for the long duration stimulus experiment.  In the short duration stimulus experiment, 
the microdialysis probe was implanted one day before the microdialysis experiment.  The probe 
was implanted into the striatum (AP: +0.0 mm, L: +2.8 mm, DV: -4.0 mm, reference point: 
bregma) and secured with dental cement.   The animals were then disconnected from the 
anesthesia apparatus and placed in a Plexiglas chamber as previously described (Dixon et al., 
1997).  Microdialysates were collected in awake, freely moving animals.  Overnight, ACSF was 
continuously perfused at 0.2 μl/min.  On the day of the experiment, flow rate was adjusted to 2.0 
μl/min for 1 hour then samples were collected every 20 minutes into a tube containing 5 μL of 
0.3 M HClO2.  Samples were immediately analyzed by HPLC.   At 60 minutes (4th collection 
time), ACSF was switched to a high potassium ACSF solution.  For short duration stimulus, 
potassium challenge (80 mM K+) was stopped and ACSF was infused forty minutes after 
beginning of stimulus (6th collection time).  For long duration stimulus, potassium challenge (100 
mM K+) continued for 180 minutes.  After microdialysis, the rats were sacrificed and the 
locations of the probes were verified.  For data analysis, micromolar concentrations of dopamine 
and dopamine metabolites are reported. 
 
2.2.7   Neurochemical analysis 
 
Neurochemical measurements were made by HPLC with CoulArray Detector using two 
four-channel analytical cells (ESA, Chelmsford, MA, USA).  Eight coulometric electrodes with 
potentials from -120 to +300 mV in 60 mV increments were used, and a C18 column was used to 
separate the analytes.  Dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic 
acid (HVA) were monitored in the microdialysates (Sigma, St. Louis, MO).  For TH activity 
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assay, L-DOPA was monitored by analyzing its levels from striatal homogenates using HPLC.  
Baseline values of dopamine below the linear range of detection were recorded as 0 μM.   
 
2.2.8   Statistical analysis 
 
The normalized TH activity levels and optical densities of TH, pser19TH, and pser40TH 
were analyzed by using unpaired Student’s T test to compare each group’s sham ipsilateral side 
to injured ipsilateral side and sham contralateral side to injured contralateral side.  Microdialysis 
data for DOPAC and HVA were analyzed using repeated measures ANOVA.  For potassium 
evoked dopamine release, the peak values were used to compare the sham injured and CCI 
injured animals.  Statistical analysis for microdialysis data was performed using a Mann-
Whitney U test.  All statistical calculations were performed by using PASW Statistics 19 (SPSS 
Inc., Chicago, IL) software. 
 
 
2.3    Results 
 
2.3.1  Total TH Levels in Striatum and Substantia Nigra After TBI: 
 
Striatal levels of TH did not show significant changes at any of the time points for both 
ipsilateral and contralateral sides (Fig. 6).  However, there was a decrease in TH levels in the 
ipsilateral injured substantia nigra compared to sham substantia nigra at 1 week after injury 
(ipsilateral sham: 100.0±10.6%, ipsilateral injured:72.6±8.7%, p≤0.05). 
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For pser19TH levels, no statistically significant differences were found at any of the time 
points in striatal tissues (Fig. 7).  For substantia nigra, no difference between sham and injured 
groups were found for the 1 day time point.  However, substantia nigra showed a significant 
decrease at 1 week (ipsilateral sham: 100.0±11.6%, ipsilateral Injured: 62.7±3.6%, p≤0.05), 
similar to the pattern of TH deficit specific to substantia nigra at 1 week (Fig. 6).  This deficit is 
reversed by 4 weeks, with no significant differences seen in both ipsilateral and contralateral 
sides.   
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Figure 6.  Western blot measurement of TH protein levels were analyzed for the striatum 
(a-c) and substantia nigra (d-f).  The striatal protein levels of TH at 1 day, 1 week, and 4 weeks 
showed no significant changes in injured groups compared to sham groups for ipsilateral and 
contralateral sides.  There was a significant decrease in TH in ipsilateral injured substantia nigra 
at 1 week after TBI, but not at 1 day and 4 weeks.  Ipsi=ipsilateral, Contra=contralateral, 
Inj=injured, *p≤0.05. 
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Figure 7. Western blot measurement of levels of pser19TH in the striatum (a-c) and 
substantia nigra (d-f).  The only significant decrease was found in ipsilateral injured substantia 
nigra compared to sham substantia nigra at 1 week post injury.  This TBI induced deficit is 
transient as there is recovery of pser19TH at 4 week time point. Ipsi=ipsilateral, 
Contra=contralateral, Inj=injured, *p≤0.05. 
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Figure 8.  Western blot data showing pser40TH levels in the striatum (a-c) and substantia 
nigra (d-f).  At 1 week, significant decreases in pser40TH levels were seen in the injured striatum 
(b) and substantia nigra (e).  Ipsi=ipsilateral, Contra=contralateral, Inj=injured, *p≤0.05. 
 
For pser40TH levels (Fig. 8), there were no alterations at 1 day.  At 1 week, pser40TH of 
ipsilateral injured striatum showed a significant decrease (ipsilateral sham: 100 ± 8.5 %, 
ipsilateral injured: 73.9 ± 7.3%, p≤0.05).  By 4 weeks, t his difference was no longer significant.  
Similarly, ipsilateral substantia nigra showed decreased pser40TH levels at 1 week (ipsilateral 
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sham: 100.0±10.3%, ipsilateral injured: 71.6±8.8%, p≤0.05).  Contralateral side also showed a 
similar decrease (contralateral sham: 100.0±10.3%, contralateral injured: 71.6±8.8%, p≤0.05).   
 
2.3.2   Timecourse of TH Activity Assay 
 
After Inhibition of AADC activity by NSD-1015 injection, L-DOPA accumulation in 
striatal tissue was detected by HPLC.  The accumulation of L-DOPA was used to assess TH 
activity level.  At 1 day after CCI (Fig. 9a), there is a no statistically significant change in TH 
activity (sham: 100.0 ± 9.7 %, injured: 138.0 ± 17.9 %).  At 1 week after CCI (Fig. 9b), TH 
activity was decreased significantly in the CCI injured animals compared to sham animals.  
(sham: 100.0 ± 10.6%, injured: 62.1 ± 8.2%, p≤0.05).  The activity levels of TH remains 
decreased up to 4 weeks (sham: 100.0 ± 5.2%, injured: 68.8 ± 6.2%, p≤0.05), (Fig. 9c). 
 
 
 
Figure 9.  TH activity assay.  The results of in-vivo TH activity assay at 1 day (a), 1 
week (b), and 4 weeks (c) after injury are shown.  Each group’s striatal DOPA levels are 
displayed ± SEM (n=6).  At 1 day after injury, there is a trend but no statistically significant 
 39 
increase in TH activity of CCI injured rats compared to sham rats.  At 1 week and 4 weeks after 
injury, there is a decrease in TH activity in injured rats compared to sham rats (p≤0.05). *p≤0.05.  
 
2.3.3   Timecourse of PKA activity assay 
 
The ipsilateral activity levels of PKA in the striatum after TBI was determined at 1 day, 1 
week, and 4 weeks (Fig. 10).  There was no significant difference between sham and injured 
striatum at 1 day (sham: 100.0 ± 5.9 %, injured: 110.0 ± 5.2 %). At 1 week, there is decreased 
PKA activity in injured rats (sham: 100.0 ± 4.2 %, injured: 87.8 ± 2.8%).  This decrease was 
reversed by 4 weeks, and no significant changes were shown in injured rats compared to sham 
rats (sham: 100.0 ± 3.2%, injured: 102.3 ± 6.0%). 
 
 
 
Figure 10.  PKA activity assay for striatal tissue.  PKA activity levels at 1 day (a), 1 
week (b), and 4 weeks (c) after injury are normalized by sham striatal PKA activity.  There were 
no significant differences between injured and sham rats at 1 day and 4 weeks.  However, 1 week 
time point showed significant decrease in injured PKA activity levels compared to shams. 
*p≤0.05. 
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2.3.4   Microdialysis: Long Duration Potassium Stimulus 
 
Striatal dopamine release and extracellular dopamine metabolite levels at 1 week time 
point was first studied to characterize injury induced dopamine dysregulation.  Microdialysis was 
used in conjunction with high performance liquid chromatography (HPLC).  One hour after 
implantation of the microdialysis probe, the experiment began.  A K+ stimulus of 100 mM was 
given for 180 minutes.  Maximal dopamine release was achieved at 40 minutes after stimulus 
application (Fig. 11).  However, no statistically significant difference was found between sham 
and injured animals (sham: 0.268 ± 0.039 μM, injured: 0.276 ± 0.058 μM).  Also, analysis of 
DOPAC and HVA levels showed no significant differences between sham and injured groups. 
      
 
 
Figure 11.  Long duration stimulus at 1 week.  Animals were compared for their 
response to 180 minute long 100mM K+ stimulus after sham or CCI injury.  There were no 
significant differences between the two groups for dopamine (a), DOPAC (b), and HVA (c).  
Black bar represents duration of K+ stimulus. 
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2.3.5   Microdialysis: Short Duration Potassium Stimulus 
 
In the second attempt to characterize the dopamine release, the protocol was refined to 
implant the probe the day before the experiment in order to reduce the effects of acute injury by 
probe placement.  On the day of the experiment, 80mM K+ stimulus was given for 40 minutes to 
induce dopamine release. 
 
 
 
Figure 12.  Potassium stimulated dopamine release.  The levels of dopamine in 
microdialysates were quantified by HPLC at 1 day (a), 1 week (b), and 4 weeks (c).  Potassium 
stimulus duration is labeled as a line between 4th and 5th collection times.  There is no significant 
alteration at 1 day between CCI injured rats (n=8) and sham injured rats (n=8).  At 1 week, there 
is a statistically significant decrease in peak dopamine levels of CCI injured rats (n=10) 
compared to sham injured rats (n=10).  By 4 weeks, there is no difference between CCI injured 
(n=7) and sham rats (n=7).  *p≤0.05. 
 
At 1 day after CCI (Fig. 12a), the peak dopamine levels of injured striata after 80 mM 
potassium stimulus were not statistically different from the peak dopamine levels of sham striata 
(sham: 0.105 ± 0.032 μM, injured: 0.153 ± 0.056 μM).  At 1 week after CCI (Fig. 12b), the peak 
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dopamine levels of injured striata showed a statistically significant decrease compared to that of 
sham striata (sham: 0.127 ± 0.027 μM, injured: 0.067 ± 0.015 μM, p≤0.05).  By 4 weeks after 
CCI, there are no significant differences between the sham and injured groups for peak dopamine 
levels (sham: 0.191 ± 0.017 μM, injured: 0.151 ± 0.024 μM) (Fig. 12c).   
 
 
 
Figure 13.  DOPAC measured by microdialysis.  The levels of dopamine metabolite 
DOPAC are quantified by HPLC at 1 day (a), 1 week (b), and 4 weeks (c) after injury.  There 
were no significant differences between CCI injured rats and sham rats at any time point. 
 
There were no significant differences between sham and injured striatal levels of DOPAC 
(Fig. 13a) and HVA (Fig. 14a) as compared by repeated measures ANOVA at 1 day.  These 
dopamine metabolites also showed no significant differences between sham and injured animals 
at 1 week (Fig. 13b, 13c) or 4 weeks after injury (Fig. 13c, 14c). 
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Figure 14.  HVA measured by microdialysis.  The levels of dopamine metabolite HVA 
are quantified by HPLC at 1 day (a), 1 week (b), and 4 weeks (c) after injury.  Repeated 
measures ANOVA found no significant differences between sham and injured groups at any of 
the 3 time points. 
 
 
2.4 Discussion 
 
In this chapter, we demonstrated for the first time a deficit in striatal TH activity 1 week 
(subacute) and 4 weeks (chronic) after TBI in rats as indicated by decreased tissue levels of L-
DOPA.  There was decreased pser40TH in the injured striatum at 1 week but not at 4 weeks.  
Neither pser19TH nor TH levels in striatum were altered by injury at any of the time points.  
However, substantia nigra content of pser40TH, pser19TH, and TH levels were all decreased in 
injured animals at 1 week.  Since TH is a rate limiting enzyme in dopamine synthesis, the 
decrease in its activity suggests a dopamine synthesis deficit.  However, a previous report of 
striatal dopamine content after TBI demonstrates no significant change at 1 week or 4 weeks 
after injury (Massucci et al., 2004).  Dopamine levels depend on both synthesis and degradation.  
Therefore, activities of monoamine oxidase and catechol-O-methyl transferase may be decreased 
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at these time points, reducing the degradation of dopamine.  Future studies are needed to 
elucidate TBI induced alterations of various synthesis and metabolizing enzymes for dopamine.  
The Western blot results of striatal pser40TH suggest decreased activity of TH, since the level of 
pser40TH correlates with enzymatic TH activity (Lindgren et al., 2000; Harada et al., 1996; 
Waymire et al., 1988).  However, the level of striatal pser19TH showed no significant decrease.  
Because a decrease in pser40TH level is consistent with a decreased activity of TH, these  data 
suggest that there is TH activity deficit in injured animals at 1 week time point.   
 
The role of pser40TH in TH activity levels are also supported by dopamine autoreceptor 
studies.  Activation of autoreceptors at dopamine terminals reduces TH phosphorylation and 
dopamine synthesis (Wolf and Roth, 1990).  Specifically pser40TH is reduced, but not pser19TH 
or pser31TH (Lindgren et al., 2001), indicating that pser40TH is responsible for TH activity.  
Also, some studies show that TH activity does not correlate with the level of pser19TH (Jedynak 
et al., 2002), but a stronger correlation with pser40TH levels (Sutherland et al., 1993).  However, 
pser19TH levels may induce conformational change in TH such that phosphorylation at serine 40 
site increases (Bevilaqua et al., 2001; Dunkley et al., 2004).  Thus, pser19TH levels may 
contribute indirectly to TH activity levels.  The current Western blot data shows decrease in TH, 
pser19TH, and pser40TH levels in substantia nigra after injury.  Collectively, these results 
suggest the possibility of dopamine synthesis deficit in nigrostriatal neurons. 
 
In this study, decreased activity of PKA is demonstrated at 1 week after TBI.  However at 
1 day and 4 weeks, there are no significant changes.  Because PKA is a major regulator of the 
serine 40 phosphorylation of TH, the activity level of PKA is in agreement with pser40TH levels 
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at 1 day, 1 week, and 4 weeks after injury.  Deficits in PKA activity at 1 week after injury may 
cause decreased TH phosphorylation, which could then reduce TH activity.  It should also be 
noted that other kinases such as protein kinase C and protein kinase G may also regulate 
pser40TH levels (Dunkley et al., 2004), although less extensively characterized than PKA’s 
effect is on pser40TH.  At 4 weeks, there is a recovery of PKA activity and pser40TH levels in 
injured striatum, but TH activity deficits are still present (Fig. 9c).  This suggests that the TH 
activity assay may be more sensitive to detecting injury induced changes compared to 
phosphorylation of TH by Western blotting. 
 
A decrease in PKA activity has been previously reported in the parietal cortex and 
hippocampus at acute time points (15 minutes to 48 hours) using a fluid percussion injury model 
(Atkins et al., 2007).  In contrast, pser40TH level and PKA activity in our study does not 
decrease at 1 day after injury.  However, this study and our current study are not directly 
comparable due to the differences in brain regions studied (hippocampus and cortex vs. striatum) 
and injury models (fluid percussion vs. CCI).  The directionality of PKA activity change may 
depend strongly on each of these factors. 
 
Dopamine release induced by potassium stimulation has been used to compare 
differences in young and aged rats (Shui et al., 1998; Stanford et al., 2000) and different dietary 
treatments (Agut et al., 2000; Wang et al., 2005).  Consistent with these previous studies, 
potassium stimulation induces dopamine release and decreases extracellular DOPAC and HVA 
concentrations in our current data.  Dopamine release is not significantly altered at 1 day after 
injury but shows a decrease at 1 week after CCI injury compared to sham injured animals.  These 
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data are in agreement with a previous study showing differences in dopamine release evoked by 
electrical stimulation of the medial forebrain bundle 2 weeks after CCI injury compared to naïve 
animals.  In that study, dopamine levels were detected by fast scanning cyclic voltammetry, and 
injured animals have reduced dopamine release compared to sham animals (Wagner et al., 2005).  
By 4 weeks, there is a recovery of dopamine release in the injured animals in the current study. 
 
Potassium stimulated dopamine release depends on newly synthesized dopamine, since 
depletion of vesicular stores of dopamine using reserpine does not alter the potassium evoked 
dopamine release (Fairbrother et al., 1990).  Thus, our microdialysis data showing decrease in 
dopamine release associated with a dopamine synthesis deficit at 1 week is consistent with a 
decrease in TH activity shown by in vivo activity assay and pser40TH Western blot results. 
 
A high intensity stimulus was applied for the microdialysis experiment in section 2.3.4: 
100mM K+ stimulus for 3 hours.  Since high potassium concentration and long duration of 
stimulus would drive the striatal dopamine synthesis and release to the maximum capacity, this 
experiment was attempted to maximize the differences between sham and injured groups.  The 
dopamine release levels gradually decreases throughout the duration of the stimulus, similar to 
the previous microdialysis experiment using multiple K+ stimulus showing gradual decrease in 
dopamine release with each stimulus (Dluzen et al., 1991; Kematani et al., 1995).  This decrease 
occurs due to depletion of the dopamine stores.  However, the high intensity potassium stimulus 
did not show any difference between sham and injured groups.   
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The protocol for potassium evoked dopamine release was changed because there was a 
concern that acute injury to the brain tissue upon implantation may be a confounding variable 
that reduced the difference in dopamine release between the two groups.  Because microdialysis 
probe implantation is damaging to the brain tissue, sufficient time is necessary for the dopamine 
system to recover before starting the experiment (Shui et al., 1998).  It was previously 
demonstrated that dopamine release on the day of the probe implantation or the day after 
implantation had different responses to tetrodotoxin sensitivity, an indicator of damage for brain 
tissue (Westerink and De Vries, 1988).   
 
In the current study, there was a significant difference between sham and injured groups 
in the short duration experiment, demonstrating that this recovery time is important for 
distinguishing TBI induced effects in dopamine release.  In addition, the stimulus was adjusted to 
a shortened duration like the previous studies (Shui et al., 1998; Stanford et al., 2000; Agut et al., 
2000; Wang et al., 2005) in order to compare the results to these studies.  The dialysate levels of 
dopamine and dopamine metabolites followed the same pattern of release as reported in these 
studies, with the dopamine levels increasing and metabolite levels decreasing upon potassium 
stimulus. 
 
The results of this chapter indicate that there are decreased striatal TH activity and 
dopamine release at a subacute time point (1 week) after TBI.  These may be important 
contributors to downstream deficits in postsynaptic mediators of dopamine signaling such as 
pDARPP-32-T34, leading to functional deficits after TBI.  In the following chapter, experiments 
using nicotine to improve presynaptic dopamine neurotransmission will be described. 
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3. The Effects of Nicotine on Presynaptic Dopamine Signaling After TBI 
 
3.1  Introduction 
 
In the previous chapter, the presynaptic deficits in nigrostriatal dopamine signaling have 
been identified to be 1) decreased nigrostriatal TH phosphorylation and activity, and 2) 
decreased striatal dopamine release.  Other members of the Dixon laboratory have previously 
demonstrated postsynaptic deficits in pDARPP32-T34 and increased PP-1 activity in striatum at 
2 weeks after TBI as discussed in Chapter 1.  The goal this study at this point was to further 
examine the role of dopamine synthesis and release deficit contributing to postsynaptic dopamine 
signaling deficits after TBI by using a pharmacological intervention that normally enhances 
dopamine signaling.  
 
Nicotine’s effect on the dopamine system has been demonstrated in the past studies.  
Experiments using both striatal slices (Wonnacott et al., 2000) and synaptosomes (Grady et al., 
1992) showed nicotine to induce dopamine release.  Nicotinic receptors’ presence in presynaptic 
locations with diversity in subunit composition has been demonstrated (Wonnacott, 1997).  
Different subtypes of nicotinic receptors are present in dopaminergic terminals compared to 
nondopaminergic terminals, possibly causing different pharmacological characteristics (Zoli et 
al., 2002).  As ligand-gated ion channels, nicotinic receptor activation leads to Na+ influx and 
neuronal depolarization.  This depolarization will then lead to activation of voltage gated Ca2+ 
channels and eventually induce dopamine release into the synapse (Grady et al., 2007).   
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Nicotine treatment also increases TH activity and TH levels in vivo as well as in vitro 
(Carr et al., 1989; Sabban et al., 2002; Hiremagalur et al., 1993).  Even in the setting of chemical 
insult to the nigrostriatal neurons by 6-hydroxydopamine, dopamine levels (Costa et al., 2001) 
and TH activity (Urbanavicius et al., 2007) were protected by nicotine treatment.  In addition, 
chronic nicotine injections have been demonstrated to enhance nicotine induced dopamine 
release in the striatum (Marshall et al., 1997) and VTA (Rahman et al., 2003) as measured by 
microdialysis.    
 
In this chapter, the effect of nicotine treatment on striatal presynaptic dopamine signaling 
was assessed.  The experiments focused on achieving Aim 2: Determine if TH activity and 
dopamine release deficits after TBI are restored by nicotine treatment.  Rats underwent 
nicotine treatment following injury in order to reverse TBI induced deficits in TH 
phosphorylation and activity, as well as dopamine release.   
 
 
3.2 Materials and Methods 
 
3.2.1 Animals 
 
One hundred and thirteen Sprague-Dawley rats (Harlan Laboratories) weighing 280-350g 
were used in this study under the guidelines set by the Institutional Animal Care and Use 
Committee of University of Pittsburgh.  Animals were housed in 12-h light/dark cycle with food 
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and water given ad libitum.  Animals were grouped into 4 conditions: Sham Saline, Injured 
Saline, Sham Nicotine, and Injured Nicotine.  Each group had n = 6-7 (TH activity assay), n = 5-
6 (microdialysis), and n=6-7 (Western blot). 
 
3.2.2 Surgery and Drug Administration 
 
Animals assigned to injury groups received TBI using the controlled cortical impact 
(CCI) device as previously described (Dixon et al., 1991).  Briefly, animals were first 
anesthetized using 5% isoflurane.  Intubation was performed, and animals were mounted on a 
stereotaxic frame.  Anesthesia was maintained using 2% isoflurane in 2:1 N2O/O2 and 
parasagittal craniectomy was performed to expose the brain to allow access for the impactor tip 
of CCI device.  TBI was induced at 4 m/s and 2.6 mm deformation (severe injury).  After injury, 
the surgical area was closed by silk sutures and animal recovery was monitored by watching for 
tail pinch and righting reflexes.  Sham injured animals underwent craniectomy only and no CCI.  
After the surgery and postoperative recovery, animals were returned to the housing facility. 
 
Rats were intraperitoneally injected with either 0.9% saline or nicotine (2.0 mg/kg, 
suspended in 0.9% saline) starting 24 hours after surgery.  The injection schedule continued 
twice daily for 7 days.  At the end of the 7 days, animals were sacrificed and striata were 
dissected out and immediately frozen in liquid nitrogen.   
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3.2.3 Microdialysis, TH Activity Assay, Western Blot 
 
All procedures were the same as those described in Chapter 2.  In addition, microdialysis 
data for dopamine was analyzed by calculating the area under the curve for the dopamine peaks 
after potassium stimulus. 
 
 
3.3 Results 
 
3.3.1.  Dose Determination 
 
Since the major regulator of dopamine signaling in medium spiny neurons is DARPP-32, 
the phosphorylation of striatal DARPP-32 was evaluated as the major outcome of nicotine 
induced enhancement of dopamine signaling.  The preliminary experiment to decide the optimal 
dose began by using previously reported doses of nicotine that increased striatal TH activity 
(Carr et al., 1989), dopamine release using microdialysis (Bednar et al., 2004), (Marshall et al., 
1997), and improvement in locomotor activity (Ksir et al., 1987; Ksir et al., 1985) and spatial 
memory (Verbois et al., 2003) ranging from 0.1-0.5 mg/kg.  
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Figure 15.  Nicotine at 0.3 mg/kg (a) and 1 mg/kg (b) were intraperitoneally injected into 
rats for 7 days, twice daily.  There were significant decreases in the level of pDARPP-32-T34 for 
injured animals that were treated with saline or nicotine. (* p≤0.05 compared to Injured Saline 
group) 
 
This preliminary experiment using either 0.3 mg/kg dose or 1.0 mg/kg dose showed a 
minor improvement in the level of striatal pDARPP-32-T34 at a higher dose of 1.0 mg/kg.  
Although the Injured Nicotine group was not significantly different from the Injured Saline 
group at either concentration, there was a modest trend of increased pDARPP-32-T34.  Based on 
these data, and previously reported studies showing increased pDARPP-32-T34 levels in striatal 
slice culture only when high nicotine concentration was applied (100μM) (Hamada et al., 2004), 
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nicotine at 3.0 mg/kg was used for one animal.  However, this dose induced temporary changes 
in the respiratory pattern of the animal lasting minutes.  Due to the fact that high dose of nicotine 
can affect neuromuscular junctions, possibly affecting respiratory muscles of rats, the test dose 
had to be lowered below 3.0 mg/kg.  A dose of 2.0 mg/kg was tested, and no respiratory pattern 
changes were noted in the animals with 2.0 mg/kg nicotine injection.  In the following 
experiments using nicotine injection, 2.0 mg/kg dose was used. 
 
3.3.2 Microdialysis Analysis of Dopamine and Dopamine Metabolites 
 
Dopamine levels in the microdialysates were analyzed by two different methods: by peak 
dopamine levels and dopamine area under the curve.  Peak dopamine levels showed significant 
between-group differences (F3,17=4.372; p≤0.05).  The Inju red Saline group had a significant 
decrease in dopamine release compared to the Sham Saline group, confirming the findings 
shown in Chapter 2.  Nicotine treatment in the Sham Nicotine group induced no significant 
change from Sham Saline.  Also, the Injured Nicotine group showed no significant difference in 
peak dopamine levels compared to the Sham Saline group, demonstrating nicotine’s effect in 
increasing striatal dopamine release.   
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Figure 16.  Microdialysis for dopamine.  High potassium ACSF was infused for 40 
minutes (represented by a black line).  Injured Saline group had decreased peak dopamine 
release compared to Sham Saline group (a), (b).  The dopamine area under the curve showed the 
same result, with Injured Saline group having significantly decreased value compared to Sham 
Saline group (c).  (Inj = Injured, Sal = Saline, Nic = Nicotine ,* p≤0.05 compared to Injured 
Saline group) 
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Dopamine area under the curve was analyzed for each of the four groups to assess for 
differences in dopamine levels over the entire duration of the potassium stimulus.  There were 
overall significant differences among the groups (F3,17=4.241; p≤0.05).  The Injured Saline group 
had significantly lower dopamine area under the curve compared to the Sham Saline group 
(p≤0.05).  However, the Injured Nicotine group was not significantly different from the Sham 
Saline group, similar to the dopamine peak level comparisons. 
 
Microdialysis of dopamine metabolites showed no significant changeamong the four 
groups (DOPAC: F3,17=0.824, p>0.05; HVA: F3,16=0.316, p>0.05).  Thus, nicotine reverses the 
dopamine deficit induced by TBI but induces no effect on extracellular dopamine metabolite 
levels. 
 
 
 
Figure 17.  Microdialysis for dopamine metabolites.  High potassium ACSF infusion 
induced transient decreases in DOPAC (a) and HVA (b) levels in microdialysates.  When the 
stimulus was stopped, the levels of metabolites returned to baseline.  Repeated measures 
ANOVA found no significant between group differences for both DOPAC and HVA.  (Inj = 
Injured, Sal = Saline, Nic = Nicotine) 
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3.3.3 Striatal TH Activity After Nicotine Treatment 
 
 
Figure 18.  TH activity assay.  DOPA accumulation in striatal tissue after injection of 
NSD-1015 was monitored using HPLC.  Injured Saline group had significant decrease in TH 
activity level compared to Sham Saline group, and Injured Nicotine had statistically significant 
increase compared to Injured Saline group. (* p≤0.05) 
 
The between group statistics showed significant differences in TH activity among the 
four groups (F3,23=14.360, p≤0.05).  The TH activity level of Injured Saline group was decreased 
compared to Sham Saline group (p≤0.05).  With nicotine treatment, injury induced deficit in TH 
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activity was reversed: Injured Nicotine group had significantly higher TH activity levels 
compared to Injured Saline group (p≤0.05). 
 
3.3.4 Tyrosine Hydroxylase Protein and Phosphorylation Levels 
 
 
 
Figure 19.  Western blots of TH, pser40TH, and pser19TH.  There was no significant 
effect of nicotine in the levels of TH or its phosphorylation at 1 week after injury. 
 
The protein levels of TH in Sham Nicotine group had an increased trend compared to the 
rest of the groups, but there was no statistically significant differences among the four groups 
(F3,20=3.068; p>0.05).  Similarly, there were no significant between group differences for 
pser19TH (F3,21=0.740; p>0.05) and pser40TH (F3,16=1.329; p>0.05). 
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3.4 Discussion 
 
In this chapter, it was demonstrated that nicotine treatment following TBI induces 
recovery of TH activity and dopamine release as measured by microdialysis.  However, 
phosphorylation of TH at both serine 19 and serine 40 was not altered, this apparent discrepancy 
may be due to the fact that the in-vivo activity assay is a more sensitive measure of TBI effects 
on dopamine compared to TH phosphoryaltion as measured by Western blots.  This difference 
will be explained in more detail below.  Overall, the current nicotine regimen following TBI 
appeared to improve presynaptic dopamine signaling: synthesis and release. 
 
The peak dopamine levels showed that nicotine treatment induces recovery of dopamine 
release in severly CCI injured animals, and that nicotine treatment of sham animals does not 
significantly change potassium evoked dopamine release as compared to saline treated sham 
animals.  Also, nicotine treatment induced partial recovery of dopamine release measured by 
dopamine peak and dopamine area under the curve.  This recovery was not large enough to show 
a significant difference in the Injured Nicotine group when compared to the Injured Saline group, 
but there was no statistically significant difference between Injured Nicotine and Sham Saline 
groups.  The graph showing the time course of dopamine release (Fig. 16a) demonstrates this 
partial recovery: although maximum dopamine level for the Injured Nicotine group was close to 
that of Sham Saline group at 40 minutes after potassium stimulus began, the delay in dopamine 
release can be seen at 20 minutes in the Injured Nicotine group (0.063±0.012μM), which shows 
much lower dopamine release compared to the Sham Saline group (0.186±0.036μM) 
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(F3,17=13.163 p≤0.05).  Thus, despite the improvement in peak dopamine release by nicotine, 
there is still a partial temporal delay in dopamine release as a result of injury. 
 
 Past studies showed increased nicotine evoked striatal dopamine release in nicotine 
treated animals (Marshall et al, 1997).  Unlike our current experiment utilizing potassium 
stimulus, the authors in this study infused nicotine by the microdialysis probes to stimulate 
dopamine release.  Our current study showed for the first time that potassium evoked dopamine 
release in nicotine treated animals and the effect of nicotine treatment in the setting of TBI. 
Potassium evoked release was used in the current study since it has been well characterized by 
previous microdialysis studies (Stanford et al., 2000; Agut et al., 2000; Shui et al., 1998; 
Gerhardt and Maloney, 1998).  In addition, potassium stimulus has been used to stimulate 
dopamine release in striatal slices (Delanoy et al., 1982) and synaptosomal preparations (Bowyer 
et al., 1987).  Unlike nicotine evoked dopamine release, which will specifically activate synapses 
via nAChRs, potassium evoked dopamine release occurs by activating neurons in the vicinity of 
the probe by depolarization.  Various terminals in the striatum are activated by depolarization of 
acting by constitutively open potassium channels (Stone, 1995), which may include not just 
dopaminergic terminals but also glutamatergic, cholinergic, and GABAeric interneurons.  Thus, 
it provides a general functional assessment of striatal dopaminergic terminals. 
 
In addition to increased striatal dopamine release, in-vivo TH activity assay showed 
decreased activity in the Injured Saline group compared to Sham Saline group, and a reversal of 
this deficit was noted in the Injured Nicotine group (Fig. 18).  Since TH activity and 
phosphorylation decreases after injury as shown in Chapter 2, nicotine treatment was aimed to 
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reverse this loss.  Past studies report that nicotine increases TH phosphorylation in situ 
(Haycock, 1991; Haycock et al., 1993) and upregulates TH transcription (Osterhout et al., 2005).  
In vitro cell culture studies also showed nicotinic receptor activation increasing TH 
phosphorylation, activity, and protein levels (Bobrovskaya et al., 2007; Craviso et al., 1992; 
Sabban and Gueorguiev, 2002).   
 
There are several suggested mechanisms of TH activation by nicotine treatment.  
Regulation of TH activity levels by intracellular Ca2+ has been previously reported (Bustos et al., 
1980).  Since tyrosine hydroxylase is mainly phosphorylated by CaMKII at serine 19 (Dunkley 
et al., 2004), increased intracellular Ca2+ can lead to CaMKII activation, which will subsequently 
lead to pser19TH increase.  Increased pser19TH may then induce a priming effect on TH 
conformational, allowing phosphorylation at serine 40 to occur at an increased rate.  In addition, 
Ca2+ activation of CaMKII can lead to activation of specific subtypes of adenylate cyclase 
(Wong et al., 1999), which can further contribute to pser40TH increase.   
 
Nicotine has also been demonstrated to induce PKC activation (Tang et al., 1997), which 
can phosphorylate TH and induce activation.  Increase in pser40TH was dependent on protein 
kinase C (PKC) 24 hours after nicotine stimulus, whereas other kinases may contribute to 
pser40TH levels at earlier times (Bobrovskaya et al., 2007).  Thus, PKC and CAMKII activation 
may be the major contributors of increased TH activity by nicotine treatment.  This reversal of 
TH activity deficit can then contribute to increased dopamine release when striatum is stimulated 
by potassium, since potassium evoked dopamine release depends on newly synthesized 
dopamine (Fairbrother et al., 1990) 
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Figure 20.  Dopamine regulation and TH activity assay.  Under physiological settings, 
AADC converts DOPA to dopamine, and dopamine release in the synapse reduces TH activity 
by the inhibitiory action of D2 autoreceptors (a).  NSD-1015 inhibits AADC, inducing 
accumulation of DOPA which can be quantified to correlate with TH activity (b).  However, 
dopamine synthesis is subsequently inhibited and inhibitory effect of D2 receptors on TH activity 
will also be decreased.  Thus, TH activity may be higher than baseline TH activity when NSD-
1015 is applied (Fig. 18). 
 
Contrary to the in-vivo TH activity data, Western blots showed no change in pser19TH 
and pser40TH levels in injured animals treated with nicotine (Fig. 19).  Also, despite an 
increased trend in TH levels in Sham Nicotine group, no change in protein levels were found.  
One possible reason for the lack of nicotine’s effect on acute changes in TH phosphorylation 
may be due to the activation of NMDA receptors.  Activation of nAChR at glutamate terminals 
can lead to glutamate release, which can then activate NMDA receptors on dopamine terminals.  
Striatal slice studies have shown that activation of NMDA receptors inhibit forskolin activated 
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TH activity and pser40TH increase (Lindgren et al., 2000).  Similarly, NMDA receptor 
activation in rat striatal synaptosomes also inhibited dopamine synthesis (Chowdhury and 
Fillenz, 1991; Desce et al., 1994) in a Ca2+ dependent manner. 
 
The discrepancy between our TH activity and Western blot data suggests that the TH 
assay may be a more sensitive measure of nicotine induced changes.  In the setting of TH activity 
assay, NSD-1015 is intraperitoneally injected into rats 30 minutes before tissue collection.  Since 
NSD-1015 inhibits AADC activity, DOPA accumulates and dopamine synthesis is inhibited.  
Dopamine depletion may occur and this may lead to reduced activation of presynaptic dopamine 
autoreceptors and consequently reduce inhibition of TH activity (Fig. 20).  Therefore in the 
setting of NSD-1015 injections, all four groups analyzed in Section 3.2.3 may have increased TH 
activity compared to baseline activity levels.  However, the striatal tissues from all four groups 
used for Western blotting may equally be subject to reduced TH activity as explained.  It is 
possible that only under increased TH activity levels as in the setting of TH activity assay, 
differences between sham and injured groups become apparent. 
 
A dose determination study initially used 0.3 mg/kg and 1.0 mg/kg doses, which did not 
achieve significant improvement in the levels of striatal pDARPP-32T34 after injury.  A higher 
dose at 2.0 mg/kg nicotine was used since previous reported studies showed increased pDARPP-
32T34 levels in striatal slices and improvement of motor function in behavioral studies with 
higher nicotine doses. 
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When low concentration of nicotine of 1.0 μM was applied to striatal slices, pDARPP-
32T34 levels decreased (Hamada et al., 2004).  This effect was abolished by treatment with 
dopamine D2 receptor antagonist raclopride.  When a higher concentration of nicotine at 100 μM 
was applied, pDARPP-32T34 level increased.  This effect was prevented by pretreatment using 
D1 receptor antagonist SCH23390.  Thus the authors of this study concluded that nicotine at 1.0 
μM activates D2 receptors, but nicotine at 100 μM activates D1 receptors.  This may occur by low 
concentration of nicotine inducing a low level of dopamine release, which is sufficient to activate 
D2 receptors since they have higher affinity for dopamine.  However, nicotine at high 
concentrations can induce higher levels of dopamine release, which will predominantly activate 
D1 receptor signaling. 
 
Also, when a range of nicotine was used in experiments testing locomotor activity (0.2 - 
5.0 mg/kg/hr) (Marks et al., 1983) and motor function (0.01 – 0.3 mg/kg/day) (Ksir et al., 1987), 
improved function was seen when animals were treated with higher doses of nicotine compared 
to lower doses.  These previous findings indicate that molecular changes and behavioral 
responses were dependent on the dose of nicotine given to animals. 
 
In this chapter, rats were treated with nicotine for 1 week after injury.  Nicotine treatment 
was shown to reverse TBI induced deficits in striatal dopamine release and TH activity.  Thus, 
presynaptic dopamine synthesis and release in striatum can be recovered by nicotine treatment 
after injury.  The preliminary data in Chapter 1 showed deficits in pDARPP-32-T34 levels after 
TBI, as well as PP-1 activity, which may be in part due to upstream dopamine release deficit.  
Thus, nicotine’s improvement of presynaptic dopamine signaling may also reverse postsynaptic 
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deficits in DARPP-32 signaling.  The next chapter will further investigate the effects of nicotine 
on downstream dopamine signaling after TBI.   
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4. The effects of nicotine on postsynaptic dopamine signaling and behavior after TBI 
 
4.1 Introduction 
 
Striatal postsynaptic dopamine terminals are regulated by various receptors, kinases, and 
second messenger proteins.  The key regulators that were monitored in this chapter are: PKA, 
DARPP-32, ERK, and CREB, all implicated in the functions of learning and memory.  As 
explained in Chapter 1: Introduction, dopamine release from the terminals of nigrostriatal 
neurons will activate dopamine receptors.  Activation of D1 receptors will lead to increased PKA 
activity, which will increase pDARPP-32-T34 levels.  The activity of PP-1 is regulated by 
pDARPP-32-T34, which functions as its inhibitor.  Inhibition of PP-1 activity will induce 
increased phosphorylation of ERK, which will eventually lead to an increase in the 
phosphorylation of CREB. 
 
Previous chapters showed decreases in TH activity and dopamine release after TBI, 
which may subsequently reduce the activation of D1 receptors and contribute to decreased 
pDARPP-32-T34 levels.  Also, the effect of TBI on presynaptic dopamine synthesis and release 
was reversed by nicotine treatment for 1 week after TBI.  In this chapter, the effect of nicotine on 
reversing the postsynaptic deficits in striatal dopamine signaling as measured by changes in 
DARPP-32 phosphorylation was investigated.  Previous studies in striatal slices have shown that 
nicotine can modulate pDARPP-32-T34 levels in vitro in a D1 or D2 receptor dependent manner 
(Hamada et al., 2004, 2005).  Whether D1 or D2 receptors were activated depended on the dose 
of nicotine applied, which controlled the amount of dopamine release.  Thus in this chapter, the 
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animals were treated with nicotine, and striatal tissues were analyzed for the activation of 
DARPP-32, ERK, and CREB.  Furthermore, the activity of PKA was monitored to understand 
the possible causes of pDARPP-32-T34 changes.  In addition, phosphorylation of DARPP-32 at 
another site threonine 75 (pDARPP-32-T75) was monitored, since pDARPP-32-T75 can inhibit 
PKA activity. 
 
Nicotine’s effect on striatal dopamine signaling also affects various behavioral measures.  
Animal studies have shown that rats with striatal lesions have spatial memory deficits (Block et 
al., 1993; Devan et al., 1999) and motor deficits (Erinoff et al., 1979; Ungerstedt 1971).  Such 
deficits were also characterized in animal models of traumatic brain injury (Smith et al., 1991; 
Dixon et al., 1999).  Previous experiments using the Morris Water Maze showed improved 
memory acquisition and retention after nicotine treatment in both physiological states (Riekkinen 
and Riekkinen, 1997; Socci et al., 1995) as well as in the setting of brain injury (Yamada et al., 
2010; Sharifzadeh et al., 2005; Brown et al., 2000).  Moreover, repeated nicotine treatments 
increase locomotor activity in rats (Smith et al., 2010) and transgenic mice expressing 
hypersensitive nAChRs show increased ambulatory behavior (Drenan et al., 2010).  Thus, 
behavioral experiments in the literature substantiate the possibility of functional improvement by 
nicotine treatment in the setting of TBI. 
 
These previous findings collectively suggest that nicotine treatment of rodents enhances 
dopamine release, DARPP-32 signaling, and result in functional improvement in behavior.  The 
activity of DARPP-32 has a key role in striatal function, and ERK and CREB are implicated in 
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functions of synaptic plasticity and memory.  Thus, nicotine induced enhancement of dopamine 
signaling after TBI may lead to recovery of both learning and motor deficits.   
 
The experiments in this chapter focused on Aim 3: Determine if enhancing TH activity 
and dopamine release by nicotine treatment can reverse the deficits in DARPP-32 activation 
and its downstream molecules, and Aim 4: Determine if enhancing striatal dopamine 
signaling by nicotine treatment results in cognitive and motor improvement in rats.  After 
molecular changes of striatum were monitored, the behavioral effect of nicotine was monitored 
by testing animals using a combination of motor and cognitive assessments. 
 
 
4.2 Materials and Methods 
 
4.2.1 Animals 
 
Eighty Sprague-Dawley rats (Harlan Laboratories) weighing 280-350g were used 
following the guidelines of the Institutional Animal Care and Use Committee of University of 
Pittsburgh.  The same feeding and housing conditions were provided for the animals as described 
in previous chapters.  Animals were grouped into 4 conditions: Sham Saline, Injured Saline, 
Sham Nicotine, and Injured Nicotine.  Each group had n = 8-10 (motor and spatial memory test) 
or n = 5-7 (Western blot and PKA activity assay). 
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4.2.2 Western Blot 
 
All procedures were identical to those described in Chapter 2.  The antibodies for 
pDARPP-32-T34, pDARPP-32-T75, pCREB, and pERK were from (Cell Signaling, Boston, 
MA). 
 
4.2.3 Surgery and Drug Administration 
 
Animals were injured using the CCI device or sham injured as described in previous 
chapters.  For Western blot and PKA activity assay, nicotine injection schedule was also 
identical to the ones described in Chapter 3: 0.9% saline or 2mg/kg nicotine injection twice daily 
for 7 days, since this regimen was able to reverse deficits in TH activity and dopamine release.  
However, animals used for motor and spatial memory tests were treated with saline or nicotine 
until 21 days post injury, at which point they were sacrificed.  During the interval days (days 6-
13) between motor testing (days 1-5) and cognitive testing (days 14-20), animals were injected 
with saline or nicotine once daily. 
 
For the initial motor testing reported in Chapter 4.3.4, nicotine injection schedule 
consisted of evening injection around 7:00 pm and morning injection at 8:00 am.  When the 
animals were tested by Beam Balance and Beam Walking Tests, the time of injection was at least 
5 hours after the last injection.  Regarding the fact that nicotine’s half life in the rat brain is 50 
minutes (Sastry et al., 1995; Ghosheh et al., 1999), 5 hours was considered sufficient time to 
avoid acute effects of nicotine treatment. 
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For the additional behavioral testing reported in Chapter 4.3.5 consisting of motor testing 
(days 1-5) and cognitive testing (days 14-20), injections were performed at 7:00 pm and 1 hour 
prior to testing.  The goal of injecting the animals 1 hour before testing was to have active effects 
of nicotine in the brain while the animals were being tested. 
 
4.2.4 Motor Test 
 
On post injury days 1-5, the motor function of animals were tested using beam-balance 
and beam-walking test, as previously described (Dixon et al., 1987; Singleton et al., 2010).  
Briefly, the animals were placed on a 1.5 cm wide beam and their duration of balance was 
recorded for up to 60 seconds 3 times daily.  The beam balance latency was assessed before the 
injury (preassessment), and for 5 days following the injury.  For beam walking test, the animals 
were trained the day before surgery to escape brightness and noise by traversing a wooden beam 
(2.5 х100cm) into a dark goal box placed at the opposite end.  On the wooden beam, there were 
four pegs between the starting location and goal box to challenge motor function as the rats 
moved from one end to the other. 
 
Like the beam balance test, animals were preassessed before the injury, and their 
performances were also recorded on post operative days 1-5.  The time taken for the animals to 
traverse the beam was recorded 4 times daily.  If the animals took longer than 60 minutes or fell, 
they were guided back to the goal box manually.  Once after reaching a goal box, animals 
remained there for 30 seconds before the next session.  The beam walking score was given by the 
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following criteria: reaching the goal box = 5 points, reaching the zone between goal box and 4th 
peg = 4 points, reaching the zone between 4th and 3rd peg = 3 points, reaching the zone between 
3rd and 2nd peg = 2 points, reaching to zone between 2nd and 1st peg = 1 point, unable to pass the 
1st peg = 0 point.  Beam-balance latency, beam-walking latency, and beam-walking score for 
each day were the mean values of all the sessions each day. 
 
4.2.5 Cognitive Test 
 
Rats were subjected to cognitive function tests beginning on postoperative day 14 for 5 
consecutive days (days 14-18).  The Morris Water Maze pool is 180 cm in diameter and 60 cm in 
depth.  Water level was 28cm deep, and a clear plastic platform of 26 cm in height was placed in 
one of the quadrants below the surface of the water.  Visual cues were displayed on the walls 
outside the pool for spatial guidance.  The position of the platform was constant throughout the 
experiment at a Southwest quadrant.  The animals were placed in the pool in one of the four 
directions randomly selected (east, west, north, and south).  They were allowed to swim in the 
pool until they found the platform, at which point the latency was recorded.  For the animals that 
did not find the platform in 120 seconds, they were manually guided to the platform and 120 
seconds were recorded as the latency.  After the animals located the platform or were guided to 
it, they were left to stand on the platform for 30 seconds before they were moved to a 30˚C 
incubator to rest between trials for 4 minutes.  Each day, a total of four trials were performed for 
each animal, and the mean latency was recorded.  On day 19, the probe trial was performed.  The 
platform was removed from the pool and the duration of swimming in the quadrant where the 
platform was previously present was recorded.  Visible platform tests were also performed for 
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days 19 and 20 to monitor the contributions of factors other than spatial memory, such as motor 
performance, motivation, and visual acuity.  For this test, the platform was raised 2.0 cm above 
the water surface, and the latency until platform was found recorded.  Only the latency to find 
the visible platform on day 20 is reported, since latency data from day 19 is considered variable 
from the past experiences of the laboratory.  A video analysis system (Any-maze, Stoelting Co., 
Wood Dale, IL) was used to record each animal’s swim speed and distance traveled. 
 
4.2.6 Statistical Analysis 
 
One way ANOVA was used to test between group differences for PKA activity assay and 
all the Western blot data using PASW software.  Motor testing (Beam Balance Duration, Beam 
Walking Latency, Beam Walking Score) as well as cognitive test (Morris Water Maze) were 
analyzed using repeated measures ANOVA.  For all statistical tests, post hoc analysis was 
performed using Tukey’s Test once between group significance was found.  For all statistical 
tests, a p-value of ≤ 0.05 was considered significant. The PKA activity levels and optical 
densities of Western blots were reported as percentage of Sham Saline group mean ± standard 
error of the mean.  Behavioral test data were reported as latency (sec), score, or % time in 
quadrant ± standard error of the mean. 
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4.3 Results 
 
4.3.1  Phosphorylation of DARPP-32 
 
The level of pDARPP-32-T34 showed significant differences between the groups 
(F3,16=8.816; p≤0.001), with Injured Saline (44.2±9.4%) and Injured Nicotine (31.9±7.3%) 
groups having significantly lower levels compared to Sham Saline group (p≤0.05).  This follows 
the previous results from the Dixon laboratory showing reducted pDARPP-32-t34 levels after 
injury, but also shows that nicotine did not reverse this loss.  When pDARPP-32-T75 levels were 
monitored, no significant between groups difference was found (F3,21=2.171; p>0.05).  However, 
a modest decrease without statistical significance was noted in the Injured Nicotine group . 
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Figure 21. Western blot data for the effects of nicotine treatment on phosphorylation of 
DARPP-32.  Two phosphorylation sites were monitored using Western blot: pDARPP-32-T34 
(a) and pDARPP-32-T75 (b).  There were significant decreases in Injured Saline and Injured 
Nicotine groups compared to Sham Saline group for pDARPP-32-T34, but no changes were seen 
for pDARPP-32-T75. 
 
4.3.2  Striatal PKA Activity After Nicotine or Saline Treatment 
 
When PKA activity assay was performed for the four groups, a significant group effect 
was found (F3,21=4.869; p≤0.01).  Nicotine treatment did not increase PKA activity in any of the 
groups compared to the saline treated groups.  Instead, there was a decrease in PKA activity of 
Injured Nicotine group compared to Sham Saline group (100.0±2.4% and 88.3±1.5% 
respectively; p≤0.01).  No statistically significant differences were found between any other 
groups. 
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Figure 22. PKA activity assay.  Injured groups consistently showed decreased trend, 
although only the Injured Nicotine group was significantly different from Sham Saline group.  (* 
p≤0.05) 
 
4.3.3   The effects of nicotine on phosphorylation of ERK and CREB 
 
Western blots showed no statistically significant differences among the four groups for 
the level of pERK (F3,20=1.557; p>0.05).  Similarly, there were no between groups differences 
for pCREB (F3,20=2.823; p>0.05).  There were no effects of injury or nicotine on 
phosphorylation of these proteins.  Although Sham Nicotine group showed a trend of increased 
pCREB, this was not statistically significant. 
 
 75 
  
 
Figure 23.  Western blots of pERK2 (a) and pCREB (b).  No significant changes were 
induced by either injury or nicotine treatment for pERK2 and pCREB. 
 
4.3.4 Motor Testing Without Acute Nicotine Dose 
 
Nicotine (2.0 mg/kg) or saline injections took place at least 5 hours prior to the test and 
second injections took place approximately 5 hours after the test to avoid acute effects of the 
drugs.  Two tests were used to assess motor function in the animals at 1 week post injury: Beam 
Balance Test (Fig. 24a) and Beam Walking Test (Fig. 24b,c).  The Beam Walking Test 
measures 2 parameters: latency to cross the beam (Fig. 24b) and farthest distance traveled on the 
beam (Fig. 24c) thus a total of 3 parameters are displayed for the motor testing.  In all three 
measures of motor function, significant differences between groups were found by repeated 
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measures ANOVA: Beam Balance Duration (F2,18=3.998, p≤0.05), Beam Walking Latency 
(F2,18=40.648, p≤0.001), and Beam Walking Score (F 2,18=21.441, p≤0.001).  Post hoc analysis 
showed significant motor deficits for all three measures in Injured Saline and Injured Nicotine 
groups from Sham Saline group, but there were no significant differences between Injured Saline 
and Injured Nicotine groups.  Thus, there was no benefit of nicotine on motor function. 
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Figure 24.  Motor function test with nicotine or saline injection 5 hours prior.  Beam 
Balance Test (a), Beam Walking Duration (b), and Beam Walking Score (c) showed significant 
between groups difference.  (Inj = Injured, Sal = Saline, Nic = Nicotine ,* p≤0.05 compared to 
Sham Saline group) 
 
4.3.5   Motor testing with acute nicotine dose 
 
After finding no improvement in Injured Nicotine group, the injection regimen was 
changed to test the animals while nicotine was still active in the brain.  Nicotine’s half life is 
reported as approximately 50 minutes (Sastry et al., 1995; Ghosheh et al., 1999).  The animals 
were previously observed to be hyperactive and have increased locomotor function up to 30 
minutes after injection, so motor testing at a time point that had no acute effects yet without 
complete metabolism of nicotine was sought.  Thus the injection schedule took place 1 hour prior 
to testing each animal.  When motor testing was completed, second daily injections were 
performed approximately 5 hours after the test.   
 
 78 
 
 
 
  
Figure 25. Motor testing with nicotine or saline injection 1 hour prior to experiment.  
Injured Saline and Injured Nicotine groups were both significantly different from Sham Saline, 
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and there was no difference between Injured Saline and Injured Nicotine groups. (Inj = Injured, 
Sal = Saline, Nic = Nicotine ,* p≤0.05 compared to Sham Saline group) 
 
Statistically significant between-groups differences were noted for Beam Balance Test 
(F3,35=47.527, p≤0.001), Beam Walking Latency (F 2,18=643.03, p≤0.001), and Beam Walking 
Score (F2,18=453.87, p≤0.001).  Simil ar to the prior motor test, Injured Saline and Injured 
Nicotine groups showed significantly lower duration on the Beam Balance Test and higher 
latency on Beam Walking Test, as well as shorter distance traveled on Beam Walking Score 
(p≤0.001 for all motor tests).  The Injured Nicotine group showed no improvement of motor 
function compared to Injured Saline group in all three measures. 
 
4.3.6   The Effects of Nicotine on Cognitive Function After TBI 
 
The data for cognitive function of animals were similar to that of motor function tests.  
There were significant between groups differences (F3,32=63.110, p≤0.001), with Injured Saline 
and Injured Nicotine groups having significantly higher platform finding latency than Sham 
Saline group (p≤0.001).  No significant  differences were found between Injured Saline and 
Injured Nicotine groups, showing that nicotine does not improve cognitive function after TBI. 
 
 
 80 
 
 
Figure 26.  Morris Water Maze data.  The animals in Injured Saline and Injured Nicotine 
groups showed significantly higher latency for finding the platform compared to Sham Saline 
group.  There was no difference between Injured Saline and Injured Nicotine groups (Inj = 
Injured, Sal = Saline, Nic = Nicotine ,* p≤0.05 compared to Sham Saline group) 
 
There were significant between group differences for the time spent in target quadrant in 
the probe phase of the experiment (F3,32=6.81, p≤0.01) (Fig. 27a).  Specifically, Injured Saline 
and Injured Nicotine groups spent less time compared to Sham Saline group in the quadrant that 
previously had the platform.  There was no significant difference between Injured Saline and 
Injured Nicotine groups.  Swim speed did not differ among the groups (F3,32=0.375, p>0.05) 
during the probe phase of the experiment (Fig. 27b).  The groups showed significant differences 
in latency for finding visible platform (F3,32=10.342, p≤0.001) (Fig. 27c). 
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Figure 27.  Assessments from probe and visible platform phases.  On days 19 and 20, the 
animals were subject to probe phase of the experiment (a) and visible platform phase (c), 
respectively.  The swim speed data were from probe phase of the experiment (b). 
 
 
4.4.   Discussion 
 
The aim of nicotine treatment was to reverse dopamine signaling deficits after TBI.  It 
was originally hypothesized that pDARPP-32-T34 deficits following injury were in part due to 
dopamine synthesis and release deficits upstream.  Nicotine increases dopamine release in the 
striatum, and activation of D1 receptors on medium spiny neurons can lead to activation of PKA 
which phosphorylates DARPP-32 to form pDARPP-32T34 (Svenningsson et al., 1998).  By 
nicotine treatment increasing dopamine synthesis and release, I had hypothesized that it would 
reverse the pDARPP-32-T34 deficit.  However, the results in this chapter show no benefit of 
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nicotine treatment (Fig. 21a).  The goal of the rest of chapter was to clarify the reason for this 
lack of nicotine’s effect on DARPP-32, by monitoring the activity of molecules upstream and 
downstream to DARPP-32. 
 
Because phosphorylation of DARPP-32 at threonine 34 site is regulated by PKA, the 
activity of PKA was monitored for the four treatment groups to further understand the lack of 
nicotine’s effect.  If nicotine induced increased dopamine signaling by activation of D1 receptors, 
PKA activity would be increased, leading to increased pDARPP-32-T34.  However, the result for 
the PKA activity assay showed a significant decrease in the activity of PKA for Injured Nicotine 
group compared to Sham Saline group, showing that nicotine treatment in fact worsened the 
injury induced deficit on the activity level of PKA (Fig. 22). 
 
In Chapter 2, the activity levels of PKA was interpreted in the context of presynaptic 
dopamine synthesis: it’s ability to phosphorylate serine 40 site of TH and thereby activating it.  
However, the majority of striatal PKA content is either glial or from medium spiny neurons 
postsynaptic to dopamine terminals since they compose about 90% of striatal neurons.  In this 
context, PKA activity will be dependent on glutamate and dopamine receptor activation on 
medium spiny neurons.  Nicotine in striatum induces both glutamate and dopamine release, 
which leads to a complex sequence of events involving multiple signaling cascades which can 
both activate or inhibit PKA (Nishi et al., 2005; Shiftlet and Balleine, 2011).   
 
Depending on the phosphorylation state, DARPP-32 can function as a bidirectional signal 
transduction molecule (Fig. 29).  When DARPP-32 is phosphorylated at threonine 75 site 
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(pDARPP-32-T75), it functions as an inhibitor of PKA, indirectly reducing pDARPP-32-T34 
and modulating PP-1 inhibition (Bibb et al., 1999).  The levels of pDARPP-32-T75 is dependent 
on the activity of cyclin depedent kinase (cdk5), which is activated by metabotropic glutamate 
receptors (mGluR) (Liu et al., 2001).  Thus, one possible reason for the lack pDARPP-32T34 
increase after nicotine treatment was the opposing effects of glutamate receptors and D1 
receptors in medium spiny neurons.  Since nicotine can also activate glutamate release by 
activating nAChRs on glutamateric terminals synapsing on to medium spiny neurons, mGluR 
can be activated, subsequently increasing pDARPP-32-T75 levels.  This may explain the 
inhibition of PKA activity and reduction of pDARPP-32-T34 levels noted.  However, the result 
in (Fig. 21b) showed no increase in pDARPP-32-T75 levels in Injured Nicotine group.  In fact, 
there was a modest decrease in pDARPP-32T-75 although no statistically significant difference 
was found.  Thus, the decreased PKA activity in Injured Nicotine group could not be explained 
by nicotine’s possible effect on pDARPP-32-T75 levels by mGluR activation. 
 
A likely reason for the decrease in PKA activity was the activity of D2 receptors (Fig. 
28).  The activation of D2 receptors leads to inhibition of adenylate cyclase via G-protein coupled 
process (Huff, 1996; Stoof and Kebabian, 1981) as well as possible activation of PP-2B, which 
can dephosphorylate pDARPP-32-T34 (Nishi et al., 1997).  Subsequently, decreased PKA 
activity and pDARPP-32-T34 levels can occur.  It is possible that the level of dopamine release 
induced by the current nicotine treatment regimen was not high enough to activate D1 receptors 
mainly.  Low level of dopamine release by nicotine at 1.0 μM in the striatum may activate 
mainly D2 receptors, which are fewer but have higher affinity (Hamada et al., 2004).  Only the 
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high nicotine concentration at 100 μM  induced higher dopamine release which activated mainly 
D1 receptors. 
 
 
 
Figure 28.  Simplified conceptual diagram of pathways modulating pDARPP-32-T34 
levels.  Activation of D1 receptors will induce pDARPP-32-T34 increase, whereas activation of 
D2 receptors and NMDA receptors will induce pDARPP-32-T34 decrease.  The activation of 
these two receptors may take place in separate neurons, but they are depicted here in the same 
cell for easy conceptual understanding. 
 
Previous reports of nicotine metabolism show relatively low levels of nicotine in the 
brain after injection.  When 0.8 mg/kg dose was injected subcutaneously, brain nicotine 
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concentration reached the maximum value of approximately 2000 pmol/g tissue (Ghosheh et al., 
1999).  When 3.0 mg/kg dose was applied by series of 10 injections, a maximum value of 
approximately 2500 pmol/g tissue was reached (Ghosheh et al., 2001).  Since these doses are 
close to the dose used in the current experiment (2.0 mg/kg), it can be assumed that the 
maximum value of approximately 2500pmol/g tissue occurred with this dose.  It is not clear how 
these nicotine tissue concentrations compare to the concentration of nicotine in striatal slice 
culture.  However, even after grossly underestimating brain tissue density to be 1.0 g/ml (density 
of water), the nicotine concentration will calculate out to be 2.0 μM.  The actual concentration of 
nicotine in striatal synapses will likely be lower, since the brain tissue density is higher than 1.0 
g/ml.  But it can be rationalized that the 2.0 mg/kg injection of nicotine will induce local striatal 
nicotine concentration closer to 1.0 μM rather than 100 μM levels, resulting in activating D2 
receptors primarily.  A weakness in this current regimen is that only one dose was used.  In order 
to provide a more comprehensive understanding of nicotine’s effects on striatal dopamine 
signaling, the experiments presented in this chapter and Chapter 3 could be repeated using 
multiple doses.  Moreover, different delivery methods such as using an osmotic pump (Verbois 
et al., 2003b) could be tested for optimal nicotine administration in future studies. 
  
The levels of pDARPP-32-T75 is not only regulated by mGluR activation, but also 
indirectly regulated by PKA (Nishi et al., 2000).  When PKA is activated, it can activate PP-2A, 
which will reduce pDARPP-32-T75 levels by dephosphorylation.  Thus, pDARPP-32-T5 and 
PKA have mutually inhibitory roles.  The current results show that neither pDARPP-32-T75 nor 
PKA activity were dominant, since both were decreased in the Injured Nicotine groups.  The 
roles of other kinases and phosphatases need to be considered to better understand these data.  
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The decreased trend of pDARPP-32-T75 and pDARPP-32-T34 in the Injured Nicotine 
group may be due to increased PP-2A and PP-2B activity, respectively.  Glutamate release 
induced by nicotine can activate NMDA receptors on medium spiny neurons, inducing Ca2+ 
influx and activation of PP-2A and PP-2B.  The activation of NMDA receptors have been shown 
to reduce pDARPP-32-T34 levels by possibly activating protein phosphatase PP-2B (King et al., 
1984; Halpain et al., 1990).  In the setting of TBI, PP-2B has an important role in regulating 
pDARPP-32-T34 levels.  Previous experiments in the Dixon laboratory have shown that TBI 
induced decreases in pDARPP-32-T34 can be reversed by FK506, a PP-2B inhibitor (Chapter 1). 
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Figure 29.  Glutamate and dopamine interaction in medium spiny neurons.  The activity 
of DARPP-32 is regulated by phosphorylation at threonine 75 and threonine 34, by complex 
interactions of glutamate and dopamine signaling.  Also, ERK is dually modulated by glutamate 
and dopamine signaling. 
 
The high intracellular Ca2+ can also reduce PKA levels, since striatum is enriched with a 
subtype of adenylate cyclase that is inhibited by Ca2+: type V calcium-inhibitable adenylate 
cyclase (Cooper et al., 1994, 1995).  Also, calcium-dependent phosphodiesterase is prevalent in 
striatal tissue (Polli and Kincaid, 1994).  These phosphodiesterases can be activated upon 
increased intracellular Ca2+, decreasing the levels of cAMP thereby reducing PKA activity.  Thus 
influx of Ca2+ via NMDA receptor activation can lead to secondary decreases in PKA activity 
levels. 
 
To further monitor postsynaptic striatal dopamine signaling, Western blots were 
performed for 2 molecules downstream of pDARPP-32T34: pERK, and pCREB, due to their 
important roles in learning and memory.  Similar to the lack of nicotine’s effect on pDARPP-32-
T34 levels, no changes were noted for pERK and pCREB.  The activation of ERK occurs by 
several upstream regulators, making it as complicated as DARPP-32 activation.  It has been 
explained in Chapter 1 that activation of D1 receptors and the following pDARPP-32-T34 
increase can lead to increased pERK levels.  In fact, ERK is modulated also by glutamate and its 
function is known as an integrator of both glutamate and dopamine signals, which can serve to 
increase or decrease ERK phosphorylation.   
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Glutamate release can activate NMDA receptors of medium spiny neurons, which will 
activate Ras/Raf pathway, leading to activation of MAPK kinase (MEK), which phosphorylates 
ERK (Shiftlet and Balleine, 2011).  However, this activation of ERK is transient since Ca2+ 
influx by NMDA receptor leads to PP-2B activation, which dephosphorylates and activates 
striatal enriched phosphatase (STEP) (Paul et al., 2003).  This activation of STEP then leads to 
dephosphorylation of ERK (Shiftlet and Balleine, 2011).  Also, D2 receptor activation can induce 
decreased pDARPP-32-T34, which will reduce the activation of ERK.  Thus, the lack of 
nicotine’s effect on pERK levels and downstream pCREB may be due to these opposing effects 
of upstream signaling pathways.   
 
The performance of rats on Beam Balance Test and Beam Walking Test can be attributed 
to different functional measures of motor skill, whereas the Morris Water Maze tests both the 
learning and retention of spatial memory.  Beam Balance Test showed both Injured Saline and 
Injured Nicotine groups to have a decreased motor performance compared to Sham Saline and 
Sham Nicotine groups.  Post hoc analysis revealed no improvement in Injured Nicotine group 
compared to Injured Saline group for Beam Walking Score and Beam Walking Latency.  In fact, 
the Beam Balance Duration for Injured Nicotine group at each of the days were lower compared 
to Injured Saline group (Fig. 25a), but there was no significant difference (p=0.067).  Thus, 
nicotine treatment did not benefit, and may even have possibly worsened performance Beam 
Balance Test in the setting of TBI.  This result is in agreement with the molecular data: PKA, 
pDARPP32-T34, pERK, and pCREB which showed no improvement by nicotine treatment. 
 
 89 
Cognitive testing by the Morris Water Maze also showed lack of benefit by nicotine 
treatment in injured animals.  There was no effect of nicotine for learning of platform location 
during the acquisition phase (days 14-19).  Also, retention of memory, tested during probe phase 
(day 20) showed no benefit of nicotine treatment.  The swim speed test showed no difference 
among the four groups, showing that the motor deficit of the injured animals was not the cause of 
higher latency to find the platform.  The data for visible platform phase (day 21) showed 
significant deficit in latency to find platform among Injured Saline group and Injured Nicotine 
group even when it was visible.  This showed that not only spatial memory, but also other 
cognitive functions such as motivation, attention, and visual recognition may have been damaged 
in injured animals and nicotine did not improve this deficit.  Similar to the motor testing, the 
cognitive behavioral data are in agreement with the lack of benefits by nicotine treatment in 
molecular experiments. 
 
Postsynaptic dopamine signaling in the striatum is regulated by complex interaction of 
multiple pathways by both glutamate and dopamine release activating various receptors and 
downstream mediators.  Although the current nicotine treatment regimen was able to induce 
recovery of TH activity and increased dopamine release as demonstrated in Chapter 3, no 
postsynaptic signaling deficits were reversed at the dose of nicotine used in these studies.  As 
described in this section, this may be due to a combination of factors: 1. nicotine inducing 
primarily D2 receptor dominant signaling, 2. Influx of Ca2+ via NMDA receptor activating PP-
2A and PP-2B, and 3.  The opposing effects of glutamate and dopamine signaling on ERK 
phosphorylation.  In addition, both cognitive and motor deficits following TBI were not reversed 
by nicotine treatment, correlating with the deficits in postsynaptic dopamine signaling. 
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5. General Discussions 
 
5.1 Further Insights into Nicotine Treatment and TBI 
 
The previous chapters demonstrated that nicotine treatment enhanced TH activity and 
dopamine release after TBI but did not improve pDARPP-32-T34 signaling and behavioral 
deficits.  In each chapter’s conclusion section, the possible causes of the current data were 
discussed and related to the previous studies in the literature.  However, there are certain 
additional issues that were not discussed in these chapters due to the lack of direct relevance to 
the data.  Nevertheless, these issues are important to review in order to better understand the 
complexity of events that we are investigating.  In this chapter, these additional issues will be 
explored for a potentially deeper understanding of TBI and the effects of nicotine treatment. 
 
5.1.1 Nicotine Receptor Desensitization 
 
Nicotine receptors are present on the soma, presynaptic area, and postsynaptic area.  
Although agonist application can lead to nAChRs activation, they are then easily desensitized 
(Wang and Sun, 2005).  Different subtypes of receptors also exhibit differences in their 
vulnerability to desensitization: α7 receptors have more rapid desensitization compared to non-
α7 receptors, and different mechanisms of desensitization occur with different concentrations of 
nAChR agonists applied (McGehee and Role, 1995; Quick and Lester, 2002).  With high level of 
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agonists ranging from micromolar to millimolar concentrations, a phenomenon known as 
classical desensitization can occur, where receptors are activated but desensitized within 
milliseconds following activation (Giniatullin et al., 2005).  Then, sensitivity will recover once 
the agonist is cleared.  In the current experiments, the local concentration of nicotine at striatal 
dopamine synapse was estimated to be in the order of μM in Chapter 3.  If desensitization of 
nAChRs occurred in the synapse, this could be a postulated to be the mechanism by which 
nicotine administration in the current project failed to enhance postsynaptic dopamine signaling 
via DARPP-32.  However, the current nicotine regimen was still able to reverse dopamine 
release and TH activity deficits. 
  
Resting tonic firing of midbrain dopamine neurons in awake, freely moving rats occurs at 
2-5 Hz, whereas action potentials will drive up the firing rate to 15-100 Hz (Hyland et al., 2002).  
Experiments with mouse striatal slices show that nicotine desensitization induces decreases in 
dopamine release under tonic firing of the neuron that is lower than in control rats.  However, 
higher frequency stimuli with bursts of action potentials induces increased levels of dopamine 
release (Exley et al., 2008).  Thus, by desensitization of nAChR, nicotine paradoxically enhances 
dopamine release in neurons undergoing phasic bursts of action potentials (Rice and Cragg, 
2004).  Even in animals chronically treated with nicotine, this enhancement of dopamine release 
occurs (Perez et al., 2008). 
 
A possible mechanism behind this increased dopamine release despite desensitization is 
by differential action of nicotine on α7 and α4β2 receptors in midbrain neurons.  In the VTA and 
substantia nigra, GABAeric neurons express α4β2 receptors and glutamatergic neurons express 
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α7 receptors.  Since α4β2 receptors are more prone to nicotine desensitization (α4β2 receptors 
IC50: ~1-60 nM, α7 receptor IC50: ~0.5-7 µM), nicotine treatment may reduce inhibitory effects 
of GABAergic interneurons on dopaminergic neurons projecting to the striatum (Dani and Zhou, 
2001; Wooltorton et al., 2003).  However, glutamate release onto dopaminergic neurons and 
subsequent activation may not be affected by desensitization due to α7 receptors being less prone 
to desensitization.  Thus, desensitization would not attenuate dopamine release but in fact may 
enhance dopamine release. 
 
5.1.2 Nicotine’s Effects on Other Neurotransmitters 
 
Although this study focused on the effects of nicotine treatment on striatal dopamine 
neurotransmission, nicotine can in fact affect various other neurotransmitter systems in different 
regions of the brain as well as the periphery.  Systemically, nicotine activates the sympathetic 
system by inducing the release of epinephrine and norepinephrine from the adrenal medulla, 
increasing heart rate and arterial blood pressure (Haas and Kuber, 1997).  However, earlier 
studies looking at rats treated with chronic nicotine administration for 4 weeks showed no effect 
on growth rate and water intake of (Bhagat, 1970).  There were no changes in the norepinephrine 
content of the brain, although the turnover rate was increased.  Chronic treatment has been 
shown to have no effect on body temperature but reduces heart rates (Marks et al., 1983).  These 
findings suggest that acute nicotine administration affects physiological parameters, but chronic 
treatment leads to tolerance development. 
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Since administration of pharmacological agents by intraperitoneal injection will affect all 
areas of the brain, nicotine will affect not just striatal dopamine and glutamate release as 
previously described but also other neurotransmitter systems.  Nicotine modulates the release of 
neurotransmitters in the hippocampus such as norepinephrine and acetylcholine, contributing to 
functions such as spatial memory and attention.  Norepinephrine release occurs by activation of 
nAChR on terminals projecting from the locus ceruleus to the hippocampus and acetylcholine 
release occurs by activation of nAChR autoreceptors on terminals projecting from the medial 
septum to the hippocampus (Wonnacott, 1997).  A synaptosomal study showed that 
norepinephrine release from hippocampal synaptosomes was 40-fold less sensitive to nicotine 
than dopamine release from striatal synaptosomes, possibly due to different composition of 
nAChR subtypes (Clarke and Reuben, 1996).  In this study, the EC50 of nicotine induced 
dopamine release in striatal synaptosomes was 0.16 μM, whereas the EC50 of nicotine induced 
norepinephrine in hippocampal synaptosomes was 6.5 μM.  Another study showed that the EC50 
of nicotine induced acetylcholine release in hippocampal synpatosomes was 0.9 μM (Wilkie et 
al., 1996).  Thus, the previous studies showing behavioral benefits of nicotine after injury is 
attributed to not only nicotine’s effects on striatal dopamine signaling, but also to a combination 
of effects on various regions of the brain and multiple neurotransmitter signaling. 
 
Nicotinic receptors are also present in the prefrontal cortex, as demonstrated by an 
autoradiography using radiolabeled nicotine binding (Clarke et al., 1985).  Since prefrontal 
cortex has important roles in cognitive functions such as working memory, planning, and 
attention (Hahn et al., 2003), nicotine’s effect in this region may explain how it improves 
cognitive function.  Also, nicotine has been demonstrated to induce dopamine release in 
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prefrontal cortex when administered locally (Marshall et al., 1997) or systemically (Nisell et al., 
1996).  Thus, cognitive enhancement of nicotine in previous TBI study (Verbois et al., 2003) as 
well as other modes of brain injury (Yamada et al., 2010; Sharifzadeh et al., 2005; Brown et al., 
2000) may be due to a combination of effects on prefrontal cortex, hippocampus, striatum, as 
well as other regions.  If the current study showed cognitive benefit of nicotine treatment, the 
next goal would have been to study nicotine’s effect on dopamine, norepinephrine, glutamate, 
and acetylcholine neurotransmission in hippocampus and frontal cortex.  The current findings 
further demonstrate that neurorecovery following TBI by a pharmacological management is 
challenging due to the involvement of multiple neurotransmitter systems and complexity of 
injury.  
 
5.1.3 The effects of nicotine on dopamine transporters 
 
Synaptic levels of dopamine are not only regulated by release but also by uptake.  
Dopamine transporter (DAT) is a membrane protein that provides the primary mechanism of 
dopamine clearance from the synapse.  It functions as a symporter that co-transports two Na+ and 
one Cl- ion down the concentration gradient along with dopamine.  Previously, other drugs that 
induce dopamine release such as cocaine and amphetamines have been reported to alter the 
surface expression of DAT (Daws et al., 2002; Kahlig et al., 2006).  In the nucleus accumbens, in 
vivo voltammetry was used to show that nicotine increases dopamine clearance (Hart and Ksir, 
1996).  Another study using the same method showed that nicotine induced faster dopamine 
clearance in the dorsal striatum as well as prefrontal cortex (Middleton et al., 2004).  Striatal 
synaptosome experiments showed that nicotine treatment increases dopamine uptake, but surface 
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expression of striatal DAT using subcellular fractionation and Western blots showed no changes 
(Middleton et al., 2007).  Since the level of DAT was not altered but the activity has increased 
with nicotine treatment, the authors proposed that phosphorylation levels of DAT may be 
changed by a kinase or a phosphatase, altering its activity.  Another molecule that modulates 
DAT is α-syn, a small chaperone like protein that binds to DAT to inhibit its activity. 
The current study reported TH activity deficits after TBI and showed that nicotine 
treatment can reverse this.  Also, dopamine release deficits occur after TBI, and nicotine 
improves dopamine release.  If nicotine reduces DAT activity, striatal extracellular dopamine 
could increase.  However, previous studies have shown that nicotine does not reduce DAT 
activity but in fact may increase it.  Since dopamine levels are increased with nicotine 
administration in previous studies using microdialysis in striatum (Marshall et al., 1997) and 
VTA (Rahman et al., 2003), the effect of nicotine on dopamine release overcomes the opposing 
effect increasing DAT activity. 
  
5.1.4 The Role of ERK in TBI 
 
Aside from its role in memory and learning, ERK is also an important mediator of 
differentiation, proliferation, and apoptosis at acute time points following TBI (Neary, 2005).  
The levels of pERK were previously reported to be increased in pericontusional cortex as early 
as 5 minutes after TBI, returning to baseline values by 6 hours (Otani et al., 2002).  Another 
report showed increased pERK levels in the cortex, subcortical white matter, thalamus, and 
hippocampus ranging from 2 hours to 72 hours post injury (Raghupathi et al., 2003).  Although 
TBI induced activation of ERK has a major role in apoptosis, it also has a major role in neuronal 
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plasticity.  Inhibition of pERK upregulation acutely after TBI is detrimental to behavioral 
outcome after TBI (Dash et al., 2002).  Application of PD98059 by intracerebroventribular 
injection 20 minutes prior to injury inhibited this upregulation of pERK but also induced 
worsening motor performance and spatial memory.  The fact that this increase in pERK was 
specific to neurons rather than astroglia (Mori et al., 2002; Dash et al., 2002) also supports the 
possibility that pERK contributes to neurogenesis and neuronal plasticity after injury, especially 
in TBI. 
 
The effects of ERK activity at chronic time points following TBI have not been 
commonly reported.  At 2-8 weeks after TBI, hippocampal levels of pERK and pCREB upon 
glutamate or potassium activation were reduced (Atkins et al., 2009).  The chronic hypofunction 
of ERK after TBI demonstrated by this study may be a contributing factor for functional deficits 
after injury.  These studies indicate that ERK activity is upregulated at acute time points but 
downregulated at chronic time points following TBI.   
 
In the current study, no changes in pERK were seen in the striatum after injury.  The time 
point used in the current study is 1 week, which is neither an acute nor a chronic time point.    
The acute increase in pERK is possibly decreased to the baseline at this point, since both 
experiments by Raghupathi et al. and Otani et al., showed reversal of injury induced pERK 
upregulation by 6 hours and 72 hours, respectively. 
 
The experimental settings in the current study were different from the setting of Atkins et 
al., in which a hippocampal slice was stimulated by glutamate or potassium.  Without glutamate 
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or potassium stimulus, basal pERK and pCREB levels were not different between sham and 
injured animals in this study.  However, when the stimulus was applied, injured animals 
displayed deficits in upregulation of pERK and pCREB.  The striatal tissue that is assessed in the 
current study was dissected from animals without glutamate or potassium stimulation.  This may 
explain why no differences were seen among the four groups for pERK and pCREB in Western 
blot data. 
 
5.1.5  Limitations of the Study and Future Suggestions 
 
One of the weaknesses of this study is the usage of only one nicotine regimen.  A full 
dose-response study for behavior has not been performed.  Since nicotine at different dose can 
have different effects on DARPP-32 phosphorylation (Hamada et al., 2004) as well as behavior 
(Ksir et al., 1987), a dose-response study may add insight into optimal treatment dose of nicotine 
for recovery from TBI induced deficits.  Also, the effects of once daily or twice daily injection 
were not compared.  The previous study using nicotine in the setting of TBI (Verbois et al., 
2003) utilized twice daily injection regimen, whereas other studies assessing the effects on 
nicotine on cognitive enhancement (Riekkinen and Riekkinen, 1997) and dopamine release 
(Rahman et al., 2003; Marshall et al., 1997) utilized once daily injection regimen.   
 
Moreover, only intraperitoneal administration of nicotine was performed, and no 
experiment was performed using subcutaneous injection or delivery by osmotic pump.  The 
current dose and delivery method was based on the same regimen that enhanced dopamine 
release and TH activity in Chapter 3.  Thus, the regimen was not optimized to yield behavioral 
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benefit.  Currently, it is not clear which regimen, dose, and delivery of nicotine is optimal for 
enhancing dopamine signaling and functional outcome after TBI.  This limitation can be 
overcome by additional experiments thoroughly characterizing the effects of each method of 
nicotine administration. 
 
Another possible limitation is the lack of characterization of different injury severities.  In 
our current study, only severe injury was performed at a velocity of 4 m/s and injury depth: 2.6 
mm.  However, previously reported studies using the CCI technique used lower values: velocity: 
2.32 m/s, depth: 2 mm (Moro et al., 2011), velocity: 3.5 m/s, depth: 1.5 mm (Verbois et al., 
2003), velocity: 1.5 m/s, depth: 2 mm (Nishibe et al., 2010).  Also, compared to the Verbois’ 
article from 2003 as well as other behavioral experimental data from our lab, the Injured Saline 
group’s motor and cognitive deficits are more pronounced.   
 
In Chapter 4, the performance of Injured Saline group on Beam Walking Latency and 
Beam Walking Score showed no signs of recovery until the last two days of the testing.  The 
final Latency and Score values were very small improvements compared to first day following 
injury.  It is possible that the severity of injury was too high, and that nicotine is not effective in 
the setting of severe injury.  Lowering the injury severity may show benefits of nicotine 
treatment in motor and cognitive function. 
 
Although we have seen enhancement of TH activity and dopamine release after nicotine 
administration, this did not enhance DARPP-32 phosphorylation.  It is not clear if TBI induced 
deficits in DARPP-32 phosphorylation is reversible or not by increasing dopamine release.  In 
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order to investigate this, chronic dopamine receptor agonist treatment should be performed 
following injury in rats.  The study should use delivery method and dose optimized by a pilot 
study.  If dopamine agonist treatment can reverse DARPP-32 phosphorylation deficit, then 
multiple agents that enhance dopamine signaling that are currently used in clinical practice such 
as methylphenidate and amphetamine can then be tested to reverse DARPP-32 phosphorylation 
deficit. 
 
As shown in Chapter 1, our lab has previously shown that FK-506 administration 
reverses TBI induced deficits in DARPP-32 phosphorylation.  Thus, combined treatment of 
nicotine and FK-506 may be able to increase DARPP-32 phosphorylation even further.  Another 
strategy is to use nicotine in conjunction with D2 receptor antagonist.  This will reduce the 
possible inhibition of cAMP and PKA signaling pathway induced by D2 receptor activation.  As 
striatal dopamine signaling is a complex phenomena involving multiple kinase cascades, 
combined drug administration may have added benefit. 
 
An additional study that can help us gain a deeper understanding of striatal dopamine 
signaling is an experiment using DARPP-32 knockout mice.  Other than nicotine, dopamine 
signal enhancing agents such as amphetamine (Evans et al., 1987), methylphenidate (Wagnet et 
al., 2009), and L-DOPA (Koeda and Takeshita, 1998; Kraus and Maki, 1997) induce functional 
benefit in the setting of TBI.  A direct experiment to test if DARPP-32 signaling has an 
important role in this functional benefit is to administer nicotine or other dopamine enhancing 
agent to DARPP-32 knockout mice following TBI.  If the deficit in pDARPP-32-T34 is an 
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important contributor to functional deficits following TBI, the functional benefits induced by 
these agents will not be seen in DARPP-32 knockout mice. 
 
5.2 Summary and Conclusion 
 
After identification of specific parameters of deficit in striatal dopamine signaling 
following TBI, this project pursued a possible therapeutic regimen using nicotine with the 
intention of enhancing dopamine synthesis and release.  The presynaptic deficits in dopamine 
signaling such as TH activity and dopamine release are recovered by nicotine treatment.  
However, activity of downstream signaling molecules such as PKA, DARPP-32, ERK, and 
CREB show no significant changes in activation after nicotine treatment, at least at the time 
points that we evaluated. In agreement with this, the behavioral data showed no benefit of 
nicotine treatment.  Thus, the data in this study suggest that: Traumatic brain injury induces 
striatal dopamine synthesis and release deficit, and a post injury nicotine treatment that was 
sufficient to induce recovery of striatal presynaptic dopamine signaling was not sufficient to 
induce striatal postsynaptic dopamine signaling or behavioral recovery.   
 
Although the original hope of this project was to identify the therapeutic potential for 
nicotine after TBI, the current data show the complexity of dopamine neurotransmission in the 
striatum. The knowledge gained from this study can be applied to devising more sophisticated 
pharmacological treatments following TBI in future studies, using a combination of agents such 
as calcineurin inhibitors and/or glutamate and dopamine receptor antagonists/agonists. 
 
 101 
 
BIBLIOGRAPHY 
 
Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, 
Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking 
alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000 
Jan;25(1):239-52. 
 
Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette 
smoking in schizophrenic patients. Am J Psychiatry. 1993 Dec;150(12):1856-61. 
 
Agut J, Ortiz JA, Wurtman RJ. Ann N Y Acad Sci. 2000;920:332-5. Cytidine 
(5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by 
microdialysis. 
 
Anden AE, Carlsson A, Dahlstroem A, Fuxe K, Hillarp NA, Larsson K. Demonstration and 
mapping out of nigrostriatal dopamine neurons, Life Sci. 3 (1964), pp. 523–530. 
 
Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for 
mammalian associative learning. Nat Neurosci. 1998 Nov;1(7):602-9. 
 
Atkins CM, Falo MC, Alonso OF, Bramlett HM, Dietrich WD. Deficits in ERK and CREB 
activation in the hippocampus after traumatic brain injury. Neurosci Lett. 2009 Aug 7;459(2):52-
6. Epub 2009 May 3. 
 
Bales JW, Wagner AK, Kline AE, Dixon CE. Persistent cognitive dysfunction after traumatic 
brain injury: A dopamine hypothesis. Neurosci Biobehav Rev. 2009 Jul;33(7):981-1003. Epub 
2009 Apr 1. Review. 
 
Bales JW. The DARPP-32/PP-1 Signaling Pathway: A Novel Therapeutic Target Following 
Traumatic Brain Injury. 2010; Doctoral dissertation, University of Pittsburgh, Pittsburgh, PA. 
 
Bhagat B. Effects of chronic administration of nicotine on storage and synthesis of noradrenaline 
in rat brain. Br J Pharmacol. 1970 Jan;38(1):86-92. 
 
Bak IJ, Hassler R, Kim JS, Kataoka K. Amantadine actions on acetylcholine and GABA in 
striatum and substantia nigra of rat in relation to behavioral changes. J Neural Transm. 1972; 
33(1):45–61. 
 
Bednar I, Friberg L, Nordberg A. Modulation of dopamine release by the nicotinic agonist 
epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated 
rats. Neurochem Int. 2004 Dec;45(7):1049-55. 
 
 102 
 
 
Beers SR, Skold A, Dixon CE, Adelson PD. Neurobehavioral effects of amantadine after 
pediatric traumatic brain injury: a preliminary report. J Head Trauma Rehabil. 2005 Sep-
Oct;20(5):450-63. 
 
Bevilaqua LR, Graham ME, Dunkley PR, von Nagy-Felsobuki EI, Dickson PW. Phosphorylation 
of Ser(19) alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation 
of Ser(40). J Biol Chem. 2001 Nov 2;276(44):40411-6. Epub 2001 Aug 13.  
 
Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, 
Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P. Phosphorylation of 
DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999 Dec 
9;402(6762):669-71. 
 
Block F, Kunkel M, Schwarz M. Quinolinic acid lesion of the striatum induces impairment in 
spatial learning and motor performance in rats. Neurosci Lett. 1993 Jan 12;149(2):126-8. 
 
Blum S, Moore AN, Adams F, Dash PK. A mitogen-activated protein kinase cascade in the 
CA1/CA2 subfield of the dorsal hippocampus is essential for long-term spatial memory. J 
Neurosci. 1999 May 1;19(9):3535-44. 
 
Bobrovskaya L, Gilligan C, Bolster EK, Flaherty JJ, Dickson PW, Dunkley PR. Sustained 
phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of 
catecholamine synthesis. J Neurochem. 2007 Jan;100(2):479-89. Epub 2006 Oct 25. 
 
Bowyer JF, Masserano JM, Weiner N. Inhibitory effects of amphetamine on potassium-
stimulated release of [3H]dopamine from striatal slices and synaptosomes. J Pharmacol Exp 
Ther. 1987 Jan;240(1):177-86. 
 
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, 
Flamm E, Leo-Summers L, Maroon J, et al. A randomized, controlled trial of 
methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the 
Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990 May 17;322(20):1405-11. 
 
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr 
DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, 
Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 
48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of 
the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute 
Spinal Cord Injury Study. JAMA. 1997 May 28;277(20):1597-604. 
 
Brown RW, Gonzalez CL, Kolb B. Nicotine improves Morris water task performance in rats 
given medial frontal cortex lesions. Pharmacol Biochem Behav. 2000 Nov;67(3):473-8. 
 
Bureau G, Carrier M, Lebel M, Cyr M. Intrastriatal inhibition of extracellular signal-regulated 
 103 
kinases impaired the consolidation phase of motor skill learning. Neurobiol Learn Mem. 2010 
Jul;94(1):107-15. Epub 2010 May 4. 
 
Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Chergui K, Svenningsson P, 
Fienberg AA, Greengard P. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls 
both striatal long-term depression and long-term potentiation, opposing forms of synaptic 
plasticity. J Neurosci. 2000 Nov 15;20(22):8443-51. 
 
Carr LA, Rowell PP, Pierce WM Jr. Effects of subchronic nicotine administration on central 
dopaminergic mechanisms in the rat. Neurochem Res. 1989 Jun;14(6):511-5. 
 
Campbell DG, Hardie DG, Vulliet PR.  Identification of four phosphorylation sites in the N-
terminal region of tyrosine hydroxylase. J Biol Chem. 1986 Aug 15;261(23):10489-92. 
 
Charpier S, Deniau JM. In vivo activity-dependent plasticity at cortico-striatal connections: 
evidence for physiological long-term potentiation. Proc Natl Acad Sci U S A. 1997 Jun 
24;94(13):7036-40. 
 
Chéramy A, Desce JM, Godeheu G, Glowinski J. Presynaptic control of dopamine synthesis and 
release by excitatory amino acids in rat striatal synaptosomes. Neurochem Int. 1994 
Aug;25(2):145-54. 
 
Chowdhury M, Fillenz M. Presynaptic adenosine A2 and N-methyl-D-aspartate receptors 
regulate dopamine synthesis in rat striatal synaptosomes. J Neurochem. 1991 May;56(5):1783-8. 
 
Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother. 2009 
Apr;10(5):839-46. 
 
Clarke PB, Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by 
nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. 
Br J Pharmacol. 1996 Feb;117(4):595-606. 
 
Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat brain: 
autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. 
J Neurosci. 1985 May;5(5):1307-15. 
 
Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive 
dysfunction in the elderly: a review of the literature. Altern Med Rev. 2004 Mar;9(1):17-31. 
 
Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH consensus 
development panel on rehabilitation of persons with traumatic brain injury. JAMA. 1999, Vols. 
282(10):974-83. 
 
Cooper DM, Mons N, Fagan K. Ca(2+)-sensitive adenylyl cyclases. Cell Signal. 1994 
Nov;6(8):823-40. Review 
 
 104 
Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and 
cAMP signalling. Nature. 1995 Mar 30;374(6521):421-4. Review 
 
Costa G, Abin-Carriquiry JA, Dajas F. Nicotine prevents striatal dopamine loss produced by 6-
hydroxydopamine lesion in the substantia nigra. Brain Res. 2001 Jan 12;888(2):336-342. 
 
Craviso GL, Hemelt VB, Waymire JC. Nicotinic cholinergic regulation of tyrosine hydroxylase 
gene expression and catecholamine synthesis in isolated bovine adrenal chromaffin cells. J 
Neurochem. 1992 Dec;59(6):2285-96. 
 
Craviso GL, Hemelt VB, Waymire JC. The transient nicotinic stimulation of tyrosine 
hydroxylase gene transcription in bovine adrenal chromaffin cells is independent of c-fos gene 
activation. Brain Res Mol Brain Res. 1995 Apr;29(2):233-44. 
 
Dani JA, Ji D, Zhou FM. Synaptic plasticity and nicotine addiction. Neuron. 2001 Aug 
16;31(3):349-52. 
 
Dash PK, Mach SA, Moore AN. The role of extracellular signal-regulated kinase in cognitive 
and motor deficits following experimental traumatic brain injury. Neuroscience. 
2002;114(3):755-67. 
 
Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF. Site-directed mutagenesis of serine 40 of 
rat tyrosine hydroxylase. Effects of dopamine and cAMP-dependent phosphorylation on enzyme 
activity. J Biol Chem. 1992 Jun 25;267(18):12639-46. 
 
Daws LC, Callaghan PD, Morón JA, Kahlig KM, Shippenberg TS, Javitch JA, Galli A. Cocaine 
increases dopamine uptake and cell surface expression of dopamine transporters. Biochem 
Biophys Res Commun. 2002 Feb 8;290(5):1545-50. 
 
Decker MW, Curzon P, Brioni JD, Arnerić SP. Effects of ABT-418, a novel cholinergic channel 
ligand, on place learning in septal-lesioned rats. Eur J Pharmacol. 1994 Aug 11;261(1-2):217-22. 
 
De Deyne CS. Therapeutic hypothermia and traumatic brain injury. Curr Opin Anaesthesiol. 
2010 Apr;23(2):258-62. 
 
Delanoy RL, Hunter GD, Dunn AJ. Catecholamine metabolism in brain slices. Determination of 
relevant precursor pool and the effects of elevated K+. Biochem Pharmacol. 1982 Oct 
15;31(20):3289-96. 
 
Deng T, Karin M. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase 
distinct from JNK and ERK.. Nature. 1994 Sep 8;371(6493):171-5. 
 
Desce JM, Godeheu G, Galli T, Glowinski J, Chéramy A. Opposite presynaptic regulations by 
glutamate through NMDA receptors of dopamine synthesis and release in rat striatal 
synaptosomes. Brain Res. 1994 Mar 21;640(1-2):205-14. 
 
 105 
Devan BD, McDonald RJ, White NM. Effects of medial and lateral caudate-putamen lesions on 
place- and cue-guided behaviors in the water maze: relation to thigmotaxis. Behav Brain Res. 
1999 Apr;100(1-2):5-14. 
 
Dixon CE, Lyeth BG, Povlishock JT, Findling RL, Hamm RJ, Marmarou A, Young HF, Hayes 
RL. A fluid percussion model of experimental brain injury in the rat. J Neurosurg. 1987 
Jul;67(1):110-9. 
 
Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL. A controlled cortical impact 
model of traumatic brain injury in the rat. J Neurosci Methods. 1991 Oct;39(3):253-62. 
 
Dixon CE, Ma X, Marion DW. Effects of CDP-choline treatment on neurobehavioral deficits 
after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. 1997 
Mar;14(3):161-9. 
 
Dixon CE, Kraus MF, Kline AE, Ma X, Yan HQ, Griffith RG, Wolfson BM, Marion DW. 
Amantadine improves water maze performance without affecting motor behavior following 
traumatic brain injury in rats. Restor Neurol Neurosci. 1999;14(4):285-294. 
 
Dluzen DE, McDermott JL, Ramirez VD. Changes in dopamine release in vitro from the corpus 
striatum of young versus aged rats as a function of infusion modes of L-dopa, potassium, and 
amphetamine. Exp Neurol. 1991; 112:153–160. 
 
Drenan RM, Grady SR, Steele AD, McKinney S, Patzlaff NE, McIntosh JM, Marks MJ, Miwa 
JM, Lester HA. Cholinergic modulation of locomotion and striatal dopamine release is mediated 
by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci. 2010 Jul  21;30(29):9877-89. 
 
Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. Tyrosine 
hydroxylase phosphorylation: regulation and consequences. J Neurochem. 2004; 91:1025-43. 
Review. 
 
English JD, Sweatt JD. Activation of p42 mitogen-activated protein kinase in hippocampal long 
term potentiation. J Biol Chem. 1996 Oct 4;271(40):24329-32. 
 
English JD, Sweatt JD. A requirement for the mitogen-activated protein kinase cascade in 
hippocampal long term potentiation. J Biol Chem. 1997 Aug 1;272(31):19103-6. 
 
Erinoff L, MacPhail RC, Heller A, Seiden LS. Age-dependent effects of 6-hydroxydopamine on 
locomotor activity in the rat. Brain Res. 1979 Mar 23;164:195-205. 
 
Evans RW, Gualtieri CT, Patterson D. Treatment of chronic closed head injury with 
psychostimulant drugs: a controlled case study and an appropriate evaluation procedure. J Nerv 
Ment Dis. 1987 Feb;175(2):106-10. 
 
 106 
Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. Alpha6-containing nicotinic 
acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus 
accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. Epub 2007 Nov 21. 
 
Feeney DM, Gonzales A, Law WA. Amphetamine restores locomotor function after motor 
cortex injury in the rat. Proc West Pharmacol Soc. 1981;24:15-7. 
 
Fitch MT, Silver J. Activated macrophages and the blood-brain barrier: inflammation after CNS 
injury leads to increases in putative inhibitory molecules. Exp Neurol. 1997 Dec;148(2):587-603. 
 
Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased 
numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995 Jul 
1;38(1):22-33. 
 
Frizzo JK, Tramontina AC, Tramontina F, Gottfried C, Leal RB, Donato R, Gonçalves CA. 
Involvement of the S100B in cAMP-induced cytoskeleton remodeling in astrocytes: a study 
using TRTK-12 in digitonin-permeabilized cells. Cell Mol Neurobiol. 2004 Dec;24(6):833-40. 
 
Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, 
Reibaud M, Pradier L, Dunbar G, Bencherif M. TC-1734: an orally active neuronal nicotinic 
acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive 
effects. CNS Drug Rev. 2004 Summer;10(2):147-66. 
 
Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR. D1 and D2 
dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. 
Science. 1990 Dec 7;250(4986):1429-32. 
 
Gerhardt GA, Maloney RE Jr. Brain Res. 1999 Jan 16;816(1):68-77. Microdialysis studies of 
basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young 
and aged Fischer 344 rats. 
 
Ghosheh O, Dwoskin LP, Li WK, Crooks PA. Residence times and half-lives of nicotine 
metabolites in rat brain after acute peripheral administration of [2-(14)C]nicotine. Drug Metab 
Dispos. 1999 Dec;27(12):1448-55. 
 
Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA. Accumulation of nicotine and its metabolites 
in rat brain after intermittent or continuous peripheral administration of [2'-(14)C]nicotine. Drug 
Metab Dispos. 2001 May;29(5):645-51. 
 
Giniatullin R, Nistri A, Yakel JL. Desensitization of nicotinic ACh receptors: shaping 
cholinergic signaling, Trends Neurosci. 2005 28:371–378. 
 
Gordon SL, Quinsy NS, Dunkley PR, Dickson PW. Tyrosine hydroxylase activity is regulated by 
two distinct dopamine-binding sites. J Neurochem. 2008 Aug;106(4):1614-23. Epub 2008 May 
31. 
 
 107 
Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. The 
subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. 
Biochem Pharmacol. 2007 Oct 15;74(8):1235-46. Epub 2007 Jul 27. 
 
Grady S, Marks MJ, Wonnacott S, Collins AC. Characterization of nicotinic receptor-mediated 
[3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem. 1992 
Sep;59(3):848-56. 
 
Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP-32/protein 
phosphatase-1 cascade. Neuron. 1999 Jul;23(3):435-47. Review. 
 
Guseva MV, Hopkins DM, Scheff SW, Pauly JR. Dietary choline supplementation improves 
behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury. J 
Neurotrauma. 2008 Aug;25(8):975-83. 
 
Haass M, Kübler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther. 1997 
Jan;10(6):657-65. Review. 
 
Halpain S, Girault JA, Greengard P. Activation of NMDA receptors induces dephosphorylation 
of DARPP-32 in rat striatal slices. Nature. 1990 Jan 25;343(6256):369-72. 
 
Hamada M, Higashi H, Nairn AC, Greengard P, Nishi A. Differential regulation of dopamine D1 
and D2 signaling by nicotine in neostriatal neurons. J Neurochem. 2004 Sep;90(5):1094-103. 
 
Hamada M, Hendrick JP, Ryan GR, Kuroiwa M, Higashi H, Tanaka M, Nairn AC, Greengard P, 
Nishi A. Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 
kDa) phosphorylation at multiple sites in neostriatal neurons. J Pharmacol Exp Ther. 2005 
Nov;315(2):872-8. Epub 2005 Jul 22. 
 
Harada L, Wu J, Haycock JW, Goldstein M. Regulation of l-DOPA biosynthesis by site-specific 
phosphorylation of tyrosine hydroxylase in AtT-20 cells expressing wild-type and serine 40-
substituted enzyme. J Neurochem. 67 1996. 67:629–635. 
 
Hart C, Ksir C. Nicotine effects on dopamine clearance in rat nucleus accumbens. J Neurochem. 
1996 Jan;66(1):216-21. 
 
Hauber W. Dopamine release in the prefrontal cortex and striatum: temporal and behavioural 
aspects. Pharmacopsychiatry. 2010 May;43 Suppl 1:S32-41. Epub 2010 May 17. Review. 
 
Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog 
Neurobiol. 1998 Dec;56(5):507-40. Review. 
 
Haycock JW. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, 40. J Biol 
Chem. 1990 Jul 15;265(20):11682-91. 
 
 108 
Haycock JW, Haycock DA. Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. 
Multiple-site phosphorylation in vivo and in synaptosomes. J Biol Chem. 1991 Mar 
25;266(9):5650-7. 
 
Haycock JW, Ahn NG, Cobb MH, Krebs EG. ERK1 and ERK2, two microtubule-associated 
protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ.  Proc 
Natl Acad Sci U S A. 1992 Mar 15;89(6):2365-9. 
 
Henry JM, Talukder NK, Lee AB Jr, Walker ML. Cerebral trauma-induced changes in corpus 
striatal dopamine receptor subtypes. J Invest Surg. 1997 Sep-Oct;10(5):281-6. 
 
Hiremagalur B, Nankova B, Nitahara J, Zeman R, Sabban EL. Nicotine increases expression of 
tyrosine hydroxylase gene. Involvement of protein kinase A-mediated pathway. J Biol Chem. 
1993 Nov 5;268(31):23704-11. 
 
Hokfelt T, Johansson O, Fuxe K, Goldstein M, Park D. 1977. Immunohistochemical studies on 
the localization and distribution of monoamine neuron systems in the rat brain II. Tyrosine 
hydroxylase in the telencephalon. Med Biol 55, 21-40. 
 
Hoofien D, Gilboa A, Vakil E, Donovick PJ. Traumatic brain injury (TBI) 10-20 years later: a 
comprehensive outcome study of psychiatric symptomatology, cognitive abilities and 
psychosocial functioning. 2001, Brain Inj, Vols. 15(3):189-209. 
 
Hovda DA, Sutton RL, Feeney DM. Amphetamine-induced recovery of visual cliff performance 
after bilateral visual cortex ablation in cats: measurements of depth perception thresholds. Behav  
Neurosci. 1989 Jun;103(3):574-84. 
 
Hornstein A, Lennihan L, Seliger G, Lichtman S, Schroeder K. Amphetamine in recovery from 
brain injury. Brain Inj. 1996 Feb;10(2):145-8. 
 
Huang LZ, Parameswaran N, Bordia T, Michael McIntosh J, Quik M. Nicotine is 
neuroprotective when administered before but not after nigrostriatal damage in rats and 
monkeys. J Neurochem. 2009 May;109(3):826-37. Epub 2009 Feb 24. 
 
Huff RM. Signal transduction pathways modulated by the D2 subfamily of dopamine receptors. 
Cell Signal. 1996 Sep;8(6):453-9. Review. 
 
Hyland BI, Reynolds JN, Hay J, Perk CG, Miller R. Firing modes of midbrain dopamine cells in 
the freely moving rat. Neuroscience. 2002;114(2):475-92. 
 
Impey S, Obrietan K, Wong ST, Poser S, Yano S, Wayman G, Deloulme JC, Chan G, Storm DR. 
Cross talk between ERK and PKA is required for Ca2+ stimulation of CREB-dependent 
transcription and ERK nuclear translocation. Neuron. 1998 Oct;21(4):869-83. 
 
Jain KK. Neuroprotection in traumatic brain injury. Drug Discov Today. 2008 Dec;13(23-
24):1082-9. Epub 2008 Oct 22. Review. 
 109 
Janson AM, Fuxe K, Agnati LF, Kitayama I, Härfstrand A, Andersson K, Goldstein M. Chronic 
nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve 
cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after 
partial hemitransection. Brain Res. 1988 Jul 12;455(2):332-45. 
 
Janson AM, Fuxe K, Sundström E, Agnati LF, Goldstein M. Chronic nicotine treatment partly 
protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced degeneration of 
nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand. 1988 Apr;132(4):589-
91.  
 
Janson AM, Meana JJ, Goiny M, Herrera-Marschitz M. Chronic nicotine treatment counteracts 
the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the 
mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett. 1991 Dec 16;134(1):88-
2. 
 
Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA.Effects of acute subcutaneous 
nicotine on attention, information processing and short-term memory in Alzheimer's disease. 
Psychopharmacology (Berl). 1992;108(4):485-94. 
 
Kahlig KM, Lute BJ, Wei Y, Loland CJ, Gether U, Javitch JA, Galli A. Regulation of dopamine 
transporter trafficking by intracellular amphetamine. Mol Pharmacol. 2006 Aug;70(2):542-8. 
Epub 2006 May 9. 
 
Kametani H, Iijima S, Spangler EL, Ingram DK, Joseph JA. In vivo assessment of striatal 
dopamine release in the aged male Fischer 344 rat. Neurobiol  Aging. 1995; 16:639–646. 
 
Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. 
alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-
amyloid-induced neurotoxicity. J Biol Chem. 2001 Apr 27;276(17):13541-6. Epub 2001 Jan 19. 
 
King MM, Huang CY, Chock PB, Nairn AC, Hemmings HC Jr, Chan KF, Greengard P. 
Mammalian brain phosphoproteins as substrates for calcineurin. J Biol Chem. 1984 Jul 
10;259(13):8080-3. 
 
Kleppe R, Toska K, Haavik J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 
proteins: evidence for a phosphoserine 40-dependent association. J Neurochem. 2001 
May;77(4):1097-107. 
 
Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM. Methylphenidate treatment following 
ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of 
function. Pharmacol Biochem Behav. 1994 Jul;48(3):773-9 
 
Kline AE, Yan HQ, Bao J, Marion DW, Dixon CE. Chronic methylphenidate treatment enhances 
water maze performance following traumatic brain injury in rats. Neurosci Lett. 2000 Feb 
25;280(3):163-6. 
 
 110 
Koeda T, Takeshita K. A case report of remarkable improvement of motor disturbances with L-
dopa in a patient with post-diffuse axonal injury. Brain Dev. 1998 Mar;20(2):124-6. 
 
Korchounov AM. Role of D1 and D2 receptors in the regulation of voluntary movements. Bull 
Exp Biol Med. 2008 Jul;146:14-7. 
 
Kraus MF, Maki P. The combined use of amantadine and l-dopa/carbidopa in the treatment of 
chronic brain injury. Brain Inj. 1997 Jun;11(6):455-60. 
 
Ksir C, Hakan R, Hall DP Jr, Kellar KJ. Exposure to nicotine enhances the behavioral stimulant 
effect of nicotine and increases binding of [3H]acetylcholine to nicotinic receptors. 
Neuropharmacology. 1985 Jun;24(6):527-31. 
 
Ksir C, Hakan RL, Kellar KJ. Chronic nicotine and locomotor activity: influences of exposure 
dose and test dose. Psychopharmacology (Berl). 1987;92(1):25-9. 
 
Lal S, Merbtiz CP, Grip JC. Modification of function in head-injured patients with Sinemet. 
Brain Inj. 1988 Jul-Sep;2(3):225-33. 
 
Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann 
MR, Ciliax BJ. Localization of D1 and D2 dopamine receptors in brain with subtype-specific 
antibodies. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8861-5. 
 
Levin ED, Lee C, Rose JE, Reyes A, Ellison G, Jarvik M, Gritz E. Chronic nicotine and 
withdrawal effects on radial-arm maze performance in rats. Behav Neural Biol. 1990 
Mar;53(2):269-76. 
 
Levin ED, Briggs SJ, Christopher NC, Rose JE. Persistence of chronic nicotine-induced 
cognitive facilitation. Behav Neural Biol. 1992 Sep;58(2):152-8. 
 
Levin ED, Rose JE, Abood L. Effects of nicotinic dimethylaminoethyl esters on working 
memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav. 1995 Jun-
Jul;51(2-3):369-73. 
 
Levin ED, Kaplan S, Boardman A. Acute nicotine interactions with nicotinic and muscarinic 
antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol. 
1997 Jun;8(2-3):236-42. 
 
Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and alpha7 nicotinic agonist, 
improves learning and memory in rats. Behav Pharmacol. 1999 Nov;10(6-7):675-80. 
 
Lindgren N, Xu ZQ, Lindskog M, Herrera-Marschitz M, Goiny M, Haycock J, Goldstein M, 
Hökfelt T, Fisone G. Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) 
and Ser(40) via activation of glutamate NMDA receptors in rat striatum. J Neurochem. 2000 
Jun;74(6):2470-7. 
 
 111 
Lindgren N, Xu Z-Q D, Herrera-Marschitz m, Haycock J, Hokfelt T, Fisone G. Dopamine D2 
receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur 
J Neurosci. 2001. Feb;13(4):773-80. 
 
Liu F, Ma XH, Ule J, Bibb JA, Nishi A, DeMaggio AJ, Yan Z, Nairn AC, Greengard P. 
Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate 
receptors. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11062-8. 
 
Losiniecki A, Shutter L. Management of traumatic brain injury. Curr Treat Options Neurol. 2010 
Mar;12(2):142-54. 
 
Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU. 
Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of 
neurotrophic factors. J Neurochem. 1998 Dec;71(6):2439-46. 
 
Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development 
and nicotinic receptors. J Pharmacol Exp Ther. 1983 Sep;226(3):817-25. 
 
Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release 
in the three ascending pathways studied by in vivo microdialysis: comparison of naive and 
chronic nicotine-treated rats. J Neurochem. 1997 Apr;68(4):1511-9. 
 
Massucci JL, Kline AE, Ma X, Zafonte RD, Dixon CE. Time dependent alterations in dopamine 
tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci Lett. 
2004 Nov 30;372(1-2):127-31. 
 
Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E, Herve D, 
Girault JA. Striatal medium-sized spiny neurons: identification by nuclear staining and study of 
neuronal subpopulations in BAC transgenic mice. PLoS One. 2009;4(3):e4770. Epub 2009 Mar 
10. 
 
McGaughy J, Decker MW, Sarter M. Enhancement of sustained attention performance by the 
nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. 
Psychopharmacology (Berl). 1999 May;144(2):175-82. 
 
McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed 
by vertebrate neurons. Annu Rev Physiol. 1995;57:521-46. 
 
McIntosh et al., 1994 T.K. McIntosh, T. Yu and T.A. Gennarelli, Alterations in regional brain 
catecholamine concentrations after experimental brain injury in the rat, J. Neurochem. 63 (1994), 
pp. 1426–1433. 
 
Meyer MJ, Megyesi J, Meythaler J, Murie-Fernandez M, Aubut JA, Foley N, Salter K, Bayley 
M, Marshall S, Teasell R. Acute management of acquired brain injury part II: an evidence-based 
review of pharmacological interventions. Brain Inj. 2010;24(5):706-21. Review.  
 
 112 
Middleton LS, Apparsundaram S, King-Pospisil KP, Dwoskin LP, Nicotine increases dopamine 
transporter function in rat striatum through a trafficking-independent mechanism 2007 Eur J 
Pharmacol 554 :128–136. 
 
Middleton LS, Cass WA, Dwoskin LP. Nicotinic receptor modulation of dopamine transporter 
function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Ther. 2004 
Jan;308(1):367-77. Epub 2003 Oct 16. 
 
Mori T, Wang X, Jung JC, Sumii T, Singhal AB, Fini ME, Dixon CE, Alessandrini A, Lo EH. 
Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. 
J Cereb Blood Flow Metab. 2002 Apr;22(4):444-52. 
 
Moro N, Ghavim SS, Hovda DA, Sutton RL. Delayed sodium pyruvate treatment improves 
working memory following experimental traumatic brain injury. Neurosci Lett. 2011 Mar 
17;491(2):158-62. Epub 2011 Jan 15. 
 
Mueller-Burke D, Koehler RC, Martin LJ. Rapid NMDA receptor phosphorylation and oxidative 
stress precede striatal neurodegeneration after hypoxic ischemia in newborn piglets and are 
attenuated with hypothermia. Int J Dev Neurosci. 2008 Feb;26(1):67-76. Epub 2007 Sep 8. 
 
Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF. 
Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized 
clinical trial. J Neurosurg. 1991 Nov;75(5):731-9. 
 
Mura A, Feldon J. Spatial learning in rats is impaired after degeneration of the nigrostriatal 
dopaminergic system. Mov Disord. 2003 Aug;18(8):860-71. 
 
Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, Martinez-Torres FJ, Wagner S. 
Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: 
effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 
2008 Jan 10;1188:198-206. Epub 2007 Nov 26. 
 
Neary JT. Protein kinase signaling cascades in CNS trauma. IUBMB Life. 2005 
Nov;57(11):711-8. 
 
Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy 
DL. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl). 
1988;95(2):171-5. 
 
Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH. Condition-independent sensitization 
of locomotor stimulation and mesocortical dopamine release following chronic nicotine 
treatment in the rat. Synapse. 1996 Apr;22(4):369-81. 
 
Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by 
dopamine. J Neurosci. 1997 Nov 1;17(21):8147-55. 
 
 113 
Nishi A, Bibb JA, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P. Regulation of 
DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct 
roles of calcineurin and protein phosphatase-2A. J Neurochem. 2002 May;81(4):832-41. 
 
Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. Glutamate regulation of 
DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling 
cascades. Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1199-204. Epub 2005 Jan 18. 
 
Nishibe M, Barbay S, Guggenmos D, Nudo RJ. Reorganization of motor cortex after controlled 
cortical impact in rats and implications for functional recovery. J Neurotrauma. 2010 
Dec;27(12):2221-32. Epub 2010 Nov 22. 
 
Nolan S. Traumatic brain injury: a review. Crit Care Nurs Q. 2005 Apr-Jun;28(2):188-94. 
Review. 
 
Osterhout CA, Sterling CR, Chikaraishi DM, Tank AW. Induction of tyrosine hydroxylase in the 
locus coeruleus of transgenic mice in response to stress or nicotine treatment: lack of activation 
of tyrosine hydroxylase promoter activity. J Neurochem. 2005 Aug;94(3):731-41. 
 
Otani N, Nawashiro H, Fukui S, Nomura N, Shima K. Temporal and spatial profile of 
phosphorylated mitogen-activated protein kinase pathways after lateral fluid percussion injury in 
the cortex of the rat brain. J Neurotrauma. 2002 Dec;19(12):1587-96. 
 
Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and 
nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
Parkinsonian toxin. Brain Res. 2003 Sep 12;984(1-2):224-32. 
 
Parks RW, Becker RE, Rippey RF, Gilbert DG, Matthews JR, Kabatay E, Young CS, Vohs C, 
Danz V, Keim P, Collins GT, Zigler SS, Urycki PG. Increased regional cerebral glucose 
metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind 
transdermal nicotine positron emission tomography study. Neuropsychol Rev. 1996 Jun;6(2):61-
79. 
 
Paul S, Nairn AC, Wang P, Lombroso PJ. NMDA-mediated activation of the tyrosine 
phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci. 2003 Jan;6(1):34-42. 
 
Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J. Chronic nicotine treatment up-regulates 
alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell 
line SH-SY5Y. Mol Pharmacol. 1997 May;51(5):776-84. 
 
Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for alpha-synuclein in the 
regulation of dopamine biosynthesis. J Neurosci. 2002 Apr 15;22(8):3090-9. 
 
Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M. Long-term nicotine treatment 
differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR 
expression and function. Mol Pharmacol. 2008 Sep;74(3):844-53. Epub 2008 Jun 26. 
 114 
 
Peterson K, Carson S, Carney N. Hypothermia treatment for traumatic brain injury: a systematic 
review and meta-analysis. J Neurotrauma. 2008 Jan;25(1):62-71. 
 
Phillips et al., 2003 J.P. Phillips, D.J. Devier and D.M. Feeney, Rehabilitation pharmacology: 
bridging laboratory work to clinical application, J. Head Trauma Rehabil. 2003. 18:342–356. 
 
Polli JW, Kincaid RL. Expression of a calmodulin-dependent phosphodiesterase isoform 
(PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci. 
1994 Mar;14(3 Pt 1):1251-61. 
 
Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson’s disease. 
Neurotoxicology. 2002. 23:581-594. 
 
Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol. 2002 
Dec;53(4):457-78. 
 
Raghupathi R, Muir JK, Fulp CT, Pittman RN, McIntosh TK. Acute activation of mitogen-
activated protein kinases following traumatic brain injury in the rat: implications for 
posttraumatic cell death. Exp Neurol. 2003 Oct;183(2):438-48. 
 
Rahman, S., J. Zhang, and W.A. Corrigall, Effects of acute and chronic nicotine on 
somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study. 
Neurosci Lett, 2003. 348(2): p. 61-4. 
 
Ralph JK, Lowes T. J R Army Med Corps. 2009 Jun;155(2):147-51. Review. Neurointensive 
care. 
 
Ramic M, Emerick AJ, Bollnow MR, O'Brien TE, Tsai SY, Kartje GL. Axonal plasticity is 
associated with motor recovery following amphetamine treatment combined with rehabilitation 
after brain injury in the adult rat. Brain Res. 2006 Sep 21;1111(1):176-86. Epub 2006 Aug 21. 
 
Rezvani AH, Bushnell PJ, Levin ED. Effects of nicotine and mecamylamine on choice accuracy 
in an operant visual signal detection task in female rats. Psychopharmacology (Berl). 2002 
Dec;164(4):369-75. Epub 2002 Sep 20. 
 
Rezvani AH, Levin ED. Nicotine-alcohol interactions and attentional performance on an operant 
visual signal detection task in female rats. Pharmacol Biochem Behav. 2003 Aug;76(1):75-83. 
 
Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat 
Neurosci. 2004 Jun;7(6):583-4. Epub 2004 May 16. 
 
Riekkinen M, Riekkinen P Jr. Nicotine and D-cycloserine enhance acquisition of water maze 
spatial navigation in aged rats. Neuroreport. 1997 Feb 10;8(3):699-703. 
 
 115 
Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, 
Brayley N, Mazairac G, Laloë V, Muñoz-Sánchez A, Arango M, Hartzenberg B, Khamis H, 
Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards 
P; CRASH trial collaborators. Effect of intravenous corticosteroids on death within 14 days in 
10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-
controlled trial. Lancet. 2004 Oct 9-15;364(9442):1321-8. 
 
Robertson GS, Vincent SR, Fibiger HC. Striatonigral projection neurons contain D1 dopamine 
receptor-activated c-fos. Brain Res. 1990 Jul 23;523(2):288-90. 
 
Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic 
nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic 
receptor subnit knockout mice. Br J Pharmacol. 2001. 132:1650-1656. 
 
Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT; Workshop Scientific 
Team and Advisory Panel Members. Classification of traumatic brain injury for targeted 
therapies. J Neurotrauma. 2008 Jul;25(7):719-38. 
 
Sabban EL, Gueorguiev VD. Effects of short- and long-term nicotine treatment on intracellular 
calcium and tyrosine hydroxylase gene expression. Ann N Y Acad Sci. 2002 Oct;971:39-44. 
 
Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR. Subunit 
composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine 
receptors mediating dopamine release in mice. Mol Pharmacol. 2004 Jun;65(6):1526-35. 
 
Sastry BV, Chance MB, Singh G, Horn JL, Janson VE. Distribution and retention of nicotine and 
its metabolite, cotinine, in the rat as a function of time. Pharmacology. 1995 Feb;50(2):128-36. 
 
Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhancement of arousal and cognition after 
traumatic brain injury. Ann Pharmacother. 2008 Feb;42(2):247-52. Epub 2008 Jan 22. 
 
Sgambato V, Pagès C, Rogard M, Besson MJ, Caboche J. Extracellular signal-regulated kinase 
(ERK) controls immediate early gene induction on corticostriatal stimulation. J Neurosci. 1998 
Nov 1;18(21):8814-25. 
 
Shames J, Treger I, Ring H, Giaquinto S. Return to work following traumatic brain injury: trends 
and challenges. Disabil Rehabil. 2007 Sep 15;29(17):1387-95. Review. 
 
Sharifzadeh M et Sharifzadeh M, Tavasoli M, Naghdi N, Ghanbari A, Amini M, Roghani A. 
Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits 
induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J Neurochem. 2005 
Nov;95(4):1078-90. Epub 2005 Sep 7. 
 
Shiflett MW, Martini RP, Mauna JC, Foster RL, Peet E, Thiels E. Cue-elicited reward-seeking 
requires extracellular signal-regulated kinase activation in the nucleus accumbens. J Neurosci. 
2008 Feb 6;28(6):1434-43. 
 116 
 
Shiflett MW, Mauna JC, Chipman AM, Peet E, Thiels E. Appetitive Pavlovian conditioned 
stimuli increase CREB phosphorylation in the nucleus accumbens. Neurobiol Learn Mem. 2009 
Oct;92(3):451-4. Epub 2009 Feb 25. 
 
Shiflett MW, Balleine BW. Contributions of ERK signaling in the striatum to instrumental 
learning and performance. Behav Brain Res. 2011 Mar 17;218(1):240-7. Epub 2010 Dec 13. 
 
Shimohama, S. and T. Kihara, Nicotinic receptor-mediated protection against beta-amyloid 
neurotoxicity. Biol Psychiatry, 2001. 49(3): p. 233-9. 
 
Shin SS, Bray ER, Zhang CQ, Dixon CE. Traumatic brain injury reduces striatal tyrosine 
hydroxylase activity and potassium-evoked dopamine release in rats. Brain Res. 2010 Nov 1. 
[Epub ahead of print] 
 
Shui HA, Peng YI, Tsai YF. Neurosci Lett. 1998 Nov 20;257(1):1-4. Recovery of high 
potassium-evoked dopamine release after depolarization challenge in the striatum of young and 
old male rats. 
 
Smith AM, Pivavarchyk M, Wooters TE, Zhang Z, Zheng G, McIntosh JM, Crooks PA, Bardo 
MT, Dwoskin LP. Repeated nicotine administration robustly increases bPiDDB inhibitory 
potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine 
release. Biochem Pharmacol. 2010 Aug 1;80(3):402-9. Epub 2010 Mar 25. 
 
Smith DH, Okiyama K, Thomas MJ, Claussen B, McIntosh TK. Evaluation of memory 
dysfunction following experimental brain injury using the Morris water maze. J Neurotrauma. 
1991 Winter;8(4):259-69. 
 
Socci DJ, Sanberg PR, Arendash GW. Nicotine enhances Morris water maze performance of 
young and aged rats. Neurobiol Aging. 1995 Sep-Oct;16(5):857-60. 
 
Stanford JA, Giardina K, Gerhardt GA. Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):411-6. In vivo 
microdialysis studies of age-related alterations in potassium-evoked overflow of dopamine in the 
dorsal striatum of Fischer 344 rats. 
 
Stone TW. CNS neurotransmitters and neuromodulators: glutamate. 1995 CRC Press, Inc. 
Florida. 
 
Strait KA, Kuczenski R. Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine 
hydroxylase. Mol Pharmacol. 1986 Jun;29(6):561-9. 
 
Sutherland C, Alterio J, Campbell DG, Le Bourdelles B, Mallet J, Haavik J, Cohen P. 
Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated 
protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. Eur J Biochem. 1993 Oct 
15;217(2):715-22. 
 
 117 
Sutton RL, Hovda DA, Feeney DM. Amphetamine accelerates recovery of locomotor function 
following bilateral frontal cortex ablation in cats. Behav Neurosci. 1989 Aug;103(4):837-41. 
 
Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, Fisone G. Activation of 
adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation 
of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience. 1998 
May;84(1):223-8. 
 
Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an 
integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004;44:269-96. Review.  
 
Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, 
Christian EP, Doherty JJ, Hudzik T, Johnson E, Mrzljak L, Piser T, Smagin GN, Wang Y, 
Widzowski D, Smith JS. Selective alpha7 nicotinic receptor activation by AZD0328 enhances 
cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol. 
2009 Oct 1;78(7):880-8. Epub 2009 Jul 16. 
 
Takada-Takatori Y, Kume T, Ohgi Y, Izumi Y, Niidome T, Fujii T, Sugimoto H, Akaike A. 
Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically 
treated with donepezil. J Neurosci Res. 2008 Dec;86(16):3575-83. 
 
Takahashi T, Yamashita H, Zhang YX, Nakamura S. Inhibitory effect of MK-801 on 
amantadine-induced dopamine release in the rat striatum. Brain Res Bull. 1996;41(6):363-7. 
 
Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, 
Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama 
S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced 
Parkinson's disease models. J Neurosci Res. 2009 Feb;87(2):576-85. 
 
Tang K, Wu H, Mahata SK, Mahata M, Gill BM, Parmer RJ, O'Connor DT. Stimulus coupling to 
transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal 
transduction pathways and the crucial roles for route of cytosolic calcium entry and protein 
kinase C. J Clin Invest. 1997 Sep 1;100(5):1180-92. 
 
Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG. Alpha-synuclein inhibits 
aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem. 2006 
Nov;99(4):1188-96. Epub 2006 Sep 18. 
 
Terry AV Jr, Risbrough VB, Buccafusco JJ, Menzaghi F. Effects of (+/-)-4-[[2-(1-methyl-2-
pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic 
acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. J 
Pharmacol Exp Ther. 2002 Apr;301(1):284-92. 
 
Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by 
rotational behaviour. Acta Physiol Scand Suppl. 1971;367:49-68. 
 
 118 
Urbanavicius J, Ferreira M, Costa G, Abin-Carriquiry JA, Wonnacott S, Dajas F. Nicotine 
induces tyrosine hydroxylase plasticity in the neurodegenerating striatum. J Neurochem. 2007; 
102:723-30. 
 
Valjent E, Pascoli V, Svenningsson P, Paul S, Enslen H, Corvol JC, Stipanovich A, Caboche J, 
Lombroso PJ, Nairn AC, Greengard P, Hervé D, Girault JA. Regulation of a protein phosphatase 
cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc 
Natl Acad Sci U S A. 2005 Jan 11;102(2):491-6. Epub 2004 Dec 17. 
 
Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R. AR-R 17779 
improves social recognition in rats by activation of nicotinic alpha7 receptors. 
Psychopharmacology (Berl). 2004 Apr;172(4):375-83. Epub 2004 Jan 15. 
 
Verbois SL, Hopkins DM, Scheff SW, Pauly JR. Chronic intermittent nicotine administration 
attenuates traumatic brain injury-induced cognitive dysfunction. Neuroscience. 
2003;119(4):1199-208. 
 
Verbois SL., Scheff SW, Pauly JR. Chronic nicotine treatment attenuates alpha 7 nicotinic 
receptor deficits following traumatic brain injury.  Neuropharmacology. 2003 Feb;44(2):224-33. 
 
Vizi ES, Lajtha A (2008).  Handbook of neurochemistry and molecular neurobiology, 3rd 
edition. New York: Springer. 
 
Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. 
Science. 1971 Oct 22;174(7):408-10. 
 
Wagner AK, Sokoloski JE, Ren D, Chen X, Khan AS, Zafonte RD, Michael AC, Dixon CE. 
Controlled cortical impact injury affects dopaminergic transmission in the rat striatum. J 
Neurochem. 2005 Oct;95(2):457-65. 
 
Wagner AK, Drewencki LL, Chen X, Santos FR, Khan AS, Harun R, Torres GE, Michael AC, 
Dixon CE. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission 
after experimental traumatic brain injury. J Neurochem. 2009 Feb;108(4):986-97. Epub 2008 
Dec 10. 
 
Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev. 2005 
Jun;48(3):420-37. 
 
Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A. Mutations in the lipid-binding domain of 
alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of 
dopamine transporter activity. Mol Cell Neurosci. 2003 Sep;24(1):91-105. 
 
Wersinger C, Vernier P, Sidhu A. Trypsin disrupts the trafficking of the human dopamine 
transporter by alpha-synuclein and its A30P mutant. Biochemistry. 2004 Feb 10;43(5):1242-53. 
 
 119 
West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor 
activation on activity states and electrophysiological properties of striatal neurons: studies 
combining in vivo intracellular recordings and reverse microdialysis. J Neurosci. 2002 Jan 
1;22(1):294-304. 
 
Westerink BH, De Vries JB. J Neurochem. 1988 Sep;51(3):683-7. Characterization of in vivo 
dopamine release as determined by brain microdialysis after acute and subchronic implantations: 
methodological aspects. 
 
Wheaton P, Mathias JL, Vink R. Impact of early pharmacological treatment on cognitive and 
behavioral outcome after traumatic brain injury in adults: a meta-analysis. J Clin 
Psychopharmacol. 2009 Oct;29(5):468-77. 
 
White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance 
in Alzheimer's disease. Psychopharmacology (Berl). 1999 Apr;143(2):158-65. 
 
Wilkie GI, Hutson P, Sullivan JP, Wonnacott S. Pharmacological characterization of a nicotinic 
autoreceptor in rat hippocampal synaptosomes. Neurochem Res. 1996 Sep;21(9):1141-8. 
 
Willmott C, Ponsford J. Efficacy of methylphenidate in the rehabilitation of attention following 
traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial. J 
Neurol Neurosurg Psychiatry. 2009 May;80(5):552-7. Epub 2008 Dec 5. 
 
Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, Kovera C, McCarten JR. 
Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol 
Biochem Behav. 1995 Jun-Jul;51(2-3):509-14. 
 
Wolf ME, Roth RH. Autoreceptor regulation of dopamine synthesis. Ann NY Acad Sci 
1990;604:323–343. 
 
Wong ST, Athos J, Figueroa XA, Pineda VV, Schaefer ML, Chavkin CC, Muglia LJ, Storm DR. 
Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term 
memory and late phase LTP. Neuron. 1999 Aug;23(4):787-98.  
 
Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997 Feb;20(2):92-8. 
Review. 
 
Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW. Presynaptic nicotinic receptors 
modulating dopamine release in the rat striatum. Eur J Pharmacol. 2000 Mar 30;393(1-3):51-8. 
 
Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution 
of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci. 2003 Apr 
15;23(8):3176-85. 
 
Yamada K, Furukawa S, Iwasaki T, Ichitani Y. Nicotine improves AF64A-induced spatial 
memory deficits in Morris water maze in rats. 2010 Neurosci Lett; 469(1):88-92. 
 120 
Yan HQ, Kline AE, Ma X, Hooghe-Peters EL, Marion DW, Dixon CE. Tyrosine hydroxylase, 
but not dopamine beta-hydroxylase, is increased in rat frontal cortex after traumatic brain injury. 
Neuroreport. 2001 Aug 8;12(11):2323-7. 
 
Yan HQ, Ma X, Chen X, Li Y, Shao L, Dixon CE. Delayed increase of tyrosine hydroxylase 
expression in rat nigrostriatal system after traumatic brain injury. Brain Res. 2007 Feb 
23;1134(1):171-9. Epub 2006 Dec 28. 
 
Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, Sharkey J. Eur 
Neuropsychopharmacol. Impaired attention is central to the cognitive deficits observed in alpha 
7 deficient mice. 2007 Jan 15;17(2):145-55. Epub 2006 May 2. 
 
Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic 
receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci. 2002 Oct 
15;22(20):8785-9. 
 
 
 
